Search

Your search keyword '"Department of Clinical Sciences"' showing total 53,928 results
Start Over Author "Department of Clinical Sciences"
53,928 results on '"Department of Clinical Sciences"'

3. Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 (REPLACECOVID)

Author

Jordana B. Cohen, MD, MSCE, Thomas C. Hanff, MD, MPH, University of Arizona, Department of Medicine, Hospital Nacional Carlos Alberto Seguín Escobedo, Arequipa, Peru, Department of Nephrology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru, Hypertension Unit, Department of Pathology, Hospital Español de Mendoza, National University of Cuyo, IMBECU-CONICET, Mendoza, Argentina, Division of Nephrology, Stanford University School of Medicine, Stanford, CA, USA, Division of Infectious Diseases, University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, ON, Canada, Unidad de VIH, Hospital Civil de Guadalajara and Universidad de Guadalajara, Guadalajara, Mexico, Universidad Católica de Buenos Aires, Buenos Aires, Argentina, Departamento de Medicina Interna, Hospital Obrero number 3 Caja Nacional de Salud, Santa Cruz de la Sierra, Bolivia, Departamento de Medicina, Hospital Alberto Barton Thompson, Callao, Peru, Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden, Division of Cardiology, University of Miami Miller School of Medicine, Miami, FL, USA, Departamento de Emergencia, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru, Division of Cardiology, Department of Medicine, Hospital Español, Buenos Aires, Argentina, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, MI, USA, Jesse Chittams, MS, Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA, Charles R Vasquez, MD, and Julio A. Chirinos, Associate Professor of Medicine at the Hospital of the University of Pennsylvania

Published
2021

5. Gelatin-Based Hybrid Hydrogels as Matrices for Organoid Culture

Author

Internal Medicine of Companion Animals, Interne geneeskunde GD, CS_STEAM, STEAM, Research Department VM - Clinical Sciences, Carpentier, Nathan, Ye, Shicheng, Delemarre, Maarten D, Van der Meeren, Louis, Skirtach, André G, van der Laan, Luc J W, Schneeberger, Kerstin, Spee, Bart, Dubruel, Peter, Van Vlierberghe, Sandra, Internal Medicine of Companion Animals, Interne geneeskunde GD, CS_STEAM, STEAM, Research Department VM - Clinical Sciences, Carpentier, Nathan, Ye, Shicheng, Delemarre, Maarten D, Van der Meeren, Louis, Skirtach, André G, van der Laan, Luc J W, Schneeberger, Kerstin, Spee, Bart, Dubruel, Peter, and Van Vlierberghe, Sandra

Published
2024

6. Detection of nephrocalcinosis using ultrasonography, micro-computed tomography, and histopathology in cats

Author

Diagnostische beeldvorming, Research Department VM - Clinical Sciences, Tang, Pak-Kan, Geddes, Rebecca F, Chang, Yu-Mei, Jepson, Rosanne E, van den Broek, Dirk Hendrik Nicolaas, Lötter, Nicola, Elliott, Jonathan, Diagnostische beeldvorming, Research Department VM - Clinical Sciences, Tang, Pak-Kan, Geddes, Rebecca F, Chang, Yu-Mei, Jepson, Rosanne E, van den Broek, Dirk Hendrik Nicolaas, Lötter, Nicola, and Elliott, Jonathan

Published
2024

7. Risk factors and implications associated with ultrasound-diagnosed nephrocalcinosis in cats with chronic kidney disease

Author

Diagnostische beeldvorming, Research Department VM - Clinical Sciences, Tang, Pak-Kan, Geddes, Rebecca F, Chang, Yu-Mei, Jepson, Rosanne E, van den Broek, Dirk Hendrik Nicolaas, Lötter, Nicola, Elliott, Jonathan, Diagnostische beeldvorming, Research Department VM - Clinical Sciences, Tang, Pak-Kan, Geddes, Rebecca F, Chang, Yu-Mei, Jepson, Rosanne E, van den Broek, Dirk Hendrik Nicolaas, Lötter, Nicola, and Elliott, Jonathan

Published
2024

10. PPP-Botnia Exercise Intervention Study

Author

Närpes Health Care Center, Närpes, Finland, Department of Social Services and Health Care, Jakobstad, Finland, and Department of Clinical Sciences, Lund University Diabetes Center, CRC, Lund University, Malmö, Sweden

Published
2014

11. Comparison of blind, ultrasound- and neurostimulator-guided methods of percutaneous inferior alveolar nerve block

Author

Heelkunde, CS_Welfare & emerging diseases, Diagnostische beeldvorming, CS_Locomotion, Anesthesiologie, Welfare & Emerging Diseases, Research Department VM - Clinical Sciences, Lloyd-Edwards, Ralph A., Ferrão - van Sommeren, Aukje, Hermans, Hanneke, Tersmette, Anne A., Veraa, Stefanie, van Loon, Johannes P.A.M., Heelkunde, CS_Welfare & emerging diseases, Diagnostische beeldvorming, CS_Locomotion, Anesthesiologie, Welfare & Emerging Diseases, Research Department VM - Clinical Sciences, Lloyd-Edwards, Ralph A., Ferrão - van Sommeren, Aukje, Hermans, Hanneke, Tersmette, Anne A., Veraa, Stefanie, and van Loon, Johannes P.A.M.

Published
2023

12. Presumed residual thymic tissue is a common finding in thoracic computed tomography in adult dogs

Author

Diagnostische beeldvorming, VPDC pathologie, CS_Locomotion, Research Department VM - Clinical Sciences, Vester, Siemone C, Bergmann, Wilhelmina, van den Broek, Dirk H N, Veraa, Stefanie, Schaafsma, Irene A, Diagnostische beeldvorming, VPDC pathologie, CS_Locomotion, Research Department VM - Clinical Sciences, Vester, Siemone C, Bergmann, Wilhelmina, van den Broek, Dirk H N, Veraa, Stefanie, and Schaafsma, Irene A

Published
2023

13. A Translational Model for Repeated Episodes of Joint Inflammation: Welfare, Clinical and Synovial Fluid Biomarker Assessment

Author

Equine Musculoskeletal Biology, CS_Locomotion, Locomotion - Equine Sciences, Research Department VM - Clinical Sciences, Kearney, Clodagh M, Korthagen, Nicoline M, Plomp, Saskia G M, Labberté, Margot C, de Grauw, Janny C, van Weeren, P René, Brama, Pieter A J, Equine Musculoskeletal Biology, CS_Locomotion, Locomotion - Equine Sciences, Research Department VM - Clinical Sciences, Kearney, Clodagh M, Korthagen, Nicoline M, Plomp, Saskia G M, Labberté, Margot C, de Grauw, Janny C, van Weeren, P René, and Brama, Pieter A J

Published
2023

14. Effect of Lavage Solution Type on Bronchoalveolar Lavage Fluid Cytology in Clinically Healthy Horses

Author

CS_Welfare & emerging diseases, Equine Internal Medicine, CS_Locomotion, Anesthesiologie, CS_Cancer, Interne geneeskunde GD, OnGo, Welfare & Emerging Diseases, Research Department VM - Clinical Sciences, Westermann, Cornélie, de Bie, Annelieke, Olave, Carla, de Grauw, Janny, Teske, Erik, Couétil, Laurent, CS_Welfare & emerging diseases, Equine Internal Medicine, CS_Locomotion, Anesthesiologie, CS_Cancer, Interne geneeskunde GD, OnGo, Welfare & Emerging Diseases, Research Department VM - Clinical Sciences, Westermann, Cornélie, de Bie, Annelieke, Olave, Carla, de Grauw, Janny, Teske, Erik, and Couétil, Laurent

Published
2023

15. Sternal abnormalities on thoracic radiographs of dogs and cats

Author

Diagnostische beeldvorming, CS_Welfare & emerging diseases, CS_Locomotion, Welfare & Emerging Diseases, Research Department VM - Clinical Sciences, van den Broek, Dirk H N, Vester, Siemone C, Tobón Restrepo, Mauricio, Veraa, Stefanie, Diagnostische beeldvorming, CS_Welfare & emerging diseases, CS_Locomotion, Welfare & Emerging Diseases, Research Department VM - Clinical Sciences, van den Broek, Dirk H N, Vester, Siemone C, Tobón Restrepo, Mauricio, and Veraa, Stefanie

Published
2023

16. Successful Clindamycin Therapy of an Infected Subcutaneous Permanent Pacing Lead in a Dog after a Failed Course with Potentiated Amoxicillin and Enrofloxacin

Author

CS_Welfare & emerging diseases, Interne geneeskunde GD, Diagnostische beeldvorming, Genetics, Welfare & Emerging Diseases, Research Department VM - Clinical Sciences, Szatmári, Viktor, van Dongen, Astrid M, Tobón Restrepo, Mauricio, den Toom, Marjolein L, Jongejan, Niels, CS_Welfare & emerging diseases, Interne geneeskunde GD, Diagnostische beeldvorming, Genetics, Welfare & Emerging Diseases, Research Department VM - Clinical Sciences, Szatmári, Viktor, van Dongen, Astrid M, Tobón Restrepo, Mauricio, den Toom, Marjolein L, and Jongejan, Niels

Published
2023

17. Contrafreeloading Indicating the Behavioural Need to Forage in Healthy and Feather Damaging Grey Parrots

Author

CS_Welfare & emerging diseases, Interne geneeskunde GD, Welfare & Emerging Diseases, Research Department VM - Clinical Sciences, van Zeeland, Yvonne R A, Schoemaker, Nico J, Lumeij, Johannes T, CS_Welfare & emerging diseases, Interne geneeskunde GD, Welfare & Emerging Diseases, Research Department VM - Clinical Sciences, van Zeeland, Yvonne R A, Schoemaker, Nico J, and Lumeij, Johannes T

Published
2023

18. Facial Image-Based Automatic Assessment of Equine Pain

Author

Sub Human-Centered Computing, Sub Social and Affective Computing, Anesthesiologie, CS_Locomotion, Sub Multimedia, Research Department VM - Clinical Sciences, Pessanha, Francisca, Salah, Albert Ali, Loon, Thijs van, Veltkamp, Remco, Sub Human-Centered Computing, Sub Social and Affective Computing, Anesthesiologie, CS_Locomotion, Sub Multimedia, Research Department VM - Clinical Sciences, Pessanha, Francisca, Salah, Albert Ali, Loon, Thijs van, and Veltkamp, Remco

Published
2023

19. Laparoscopic vs. open adrenalectomy: perioperative data and survival analysis in 70 dogs with an adrenal tumor

Author

Interne geneeskunde GD, CS_Cancer, CS_Welfare & emerging diseases, CS_Locomotion, Anesthesiologie, VPDC pathologie, dPB CR, Veterinair Pathologisch Diagnostisch Cnt, LS Pathologie, Chirurgie, Pathology, Locomotion - Surgery (CA), OnGo, Welfare & Emerging Diseases, Research Department VM - Clinical Sciences, Bokhorst, Kirsten L. van, Galac, Sara, Kooistra, Hans S., Grauw, Janny C. de, Teske, Erik, Grinwis, Guy C. M., Nimwegen, Sebastiaan A. van, Interne geneeskunde GD, CS_Cancer, CS_Welfare & emerging diseases, CS_Locomotion, Anesthesiologie, VPDC pathologie, dPB CR, Veterinair Pathologisch Diagnostisch Cnt, LS Pathologie, Chirurgie, Pathology, Locomotion - Surgery (CA), OnGo, Welfare & Emerging Diseases, Research Department VM - Clinical Sciences, Bokhorst, Kirsten L. van, Galac, Sara, Kooistra, Hans S., Grauw, Janny C. de, Teske, Erik, Grinwis, Guy C. M., and Nimwegen, Sebastiaan A. van

Published
2023

20. Correlates to psychological distress in frail older community-dwellers undergoing lockdown during the COVID-19 pandemic

Author

Castellano-Tejedor, Carmina, Pérez, Laura M., Soto-Bagaria, Luis, Risco, Ester, Mazo, Maria Victoria, Gómez, Ana, Salvador Sara, Daniel, Yanguas, Javier, Enfedaque, María B., Morandi, Alessandro, Font, Mariona, Davey, Vanessa, Inzitari, Marco, Università Di Milano. Department of Clinical Sciences and Community Health, IRCCS Istituti Clinici Scientifici Maugeri. Geriatric Unit, Universitat Autònoma de Barcelona. Departament de Medicina, and Universitat Oberta de Catalunya. Facultat de Ciències de la Salut

Subjects
Male, Frailty, Frail Elderly, COVID-19, Psychological distress, Psychological Distress, Ageing, Communicable Disease Control, Lockdown, Humans, Female, Geriatrics and Gerontology, Pandemics, Aged
Abstract

Background This study identifies correlates of the lockdown’s psychological distress in frail older community-dwellers (Catalonia, Spain). Methods Participants from a community frailty intervention program, with a comprehensive geriatric assessment within the 12-months pre-lockdown and COVID-19 free during the first pandemic wave (March–May 2020), underwent a phone assessment past the lockdown to assess COVID-19-related emotional distress (DME) as well as other sociodemograhic, clinical and psychosocial factors. Results Of the 94 frail older adults (age = 82,34 ± 6,12 years; 68,1% women; 38,3% living alone), 84,9% were at risk of experiencing moderate-to-high psychological distress, according to the backward stepwise logistic regression model obtained (χ2 = 47,007, p 2 = 0,528), based on the following factors: absence of depressive symptoms before lockdown (OR = 0,12, p = 0,014, 95%CI[0,023–0,647]), not carrying out leisure activities during lockdown (OR = 0,257, p = 0,023, 95%CI[0,079–0,832]) and currently experiencing high malaise due to COVID-19 situation (OR = 1,504, p Discussion These findings suggest that it is necessary to favour a prior overall health status and to empower frail older community-dwellers in the use of a broad repertoire of coping strategies in the face of adversity to foster mental health and keep at bay the potential emotional impact of the situation generated by the COVID pandemic.

Published
2022

21. Cross- Cultural Adaptation and Validation of the Italian Version of SWAL-QOL

Author

Daniela, Ginocchio1, Enrico, Alfonsi2, Francesco, Mozzanica3, Accornero, Anna Rosa, Antonella, Bergonzoni5, Giulia, Chiarello6, Nicoletta De Luca6, Daniele, Farneti7, Simonelli, Marilia8, Paola, Calcagno8, Valentina, Turroni7, Antonio Schindler3, 1 Audiology Unit, Department of Clinical Sciences, Community, Health, University of Milan, Fondazione, Irccs, Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, 2 Department of Neurophysiology, Neurorehabilitation, National Institute of Neurology, Mondino’’ Foundation, ‘. ‘. C., Irccs, University of Pavia, Pavia, Italy, 3 Phoniatric Unit, Department of Biomedical, Clinical, Sacco’’, Sciences ‘. ‘. L., Italy, 4 Department of Surgical Sciences, University of Turin, Turin, Italy, 5 Department of Rehabilitation Medicine, San, Giorgio, Hospital, University of Ferrara, Ferrara, Italy, 6 Department of Otorhinolaryngology, University Hospital of Ferrara, Italy, 7 Audiology Phoniatrics Unit, Infermi, Hospital, Rimini, Italy, 8 Speech, Swallowing Rehabilitation Service, ‘‘Santa Lucia’’ Foundation IRCCS, and Rome, Italy

Subjects
Dysphagia-outcome-self-assessment
Published
2016

22. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.

Author

INSERM, U897 - INSERM, U897, Stichting HIV Monitoring, Amsterdam, the Netherlands - Stichting HIV Monitoring, Amsterdam, Hospital de Santa Maria, Clinica Universitaria de Doenças Infecciosas, Lisbon, Portugal - Hospital de Santa Maria, Clinica Universitaria de Doenças Infecciosas, Lisbon, UCL - SSS/IREC/MBLG - Pôle de Microbiologie médicale, Hospital Carlos III, Department of Infectious Diseases, Madrid, Spain - Hospital Carlos III, Department of Infectious Diseases, Madrid, Hôpitaux Universitaires de Genève, Service de Maladies Infectieuses, Unite VIH/SIDA, Geneva, Switzerland - Hôpitaux Universitaires de Genève, Service de Maladies Infectieuses, Unite VIH/SIDA, Geneva, University of Milan, Department of Clinical Sciences "L. Sacco", Section of Infectious Diseases, Milan, Italy - University of Milan, Department of Clinical Sciences "L. Sacco", Section of Infectious Diseases, APHP, Hôpital Bichat - Claude Bernard, Laboratoire de Virologie; Paris VII Denis Diderot University - APHP, Hôpital Bichat - Claude Bernard, Laboratoire de Virologie; Paris VII Denis Diderot University, INSERM, U897; University Bordeaux Segalen - INSERM, U897; University Bordeaux Segalen, Paris VII Denis Diderot University; APHP, Hôpital Bichat-Claude Bernard, Service de Maladies infectieuses et Tropicales, Paris, France - Paris VII Denis Diderot University; APHP, Hôpital Bichat-Claude Bernard, Service de Maladies infectieuses et Tropicales, Benard, Antoine, van Sighem, Ard, Taieb, Audrey, Valadas, Emilia, Ruelle, Jean, Soriano, Vicente, Calmy, Alexandra, Balotta, Claudia, Damond, Florence, Brun-Vezinet, Françoise, Chene, Geneviève, Matheron, Sophie, INSERM, U897 - INSERM, U897, Stichting HIV Monitoring, Amsterdam, the Netherlands - Stichting HIV Monitoring, Amsterdam, Hospital de Santa Maria, Clinica Universitaria de Doenças Infecciosas, Lisbon, Portugal - Hospital de Santa Maria, Clinica Universitaria de Doenças Infecciosas, Lisbon, UCL - SSS/IREC/MBLG - Pôle de Microbiologie médicale, Hospital Carlos III, Department of Infectious Diseases, Madrid, Spain - Hospital Carlos III, Department of Infectious Diseases, Madrid, Hôpitaux Universitaires de Genève, Service de Maladies Infectieuses, Unite VIH/SIDA, Geneva, Switzerland - Hôpitaux Universitaires de Genève, Service de Maladies Infectieuses, Unite VIH/SIDA, Geneva, University of Milan, Department of Clinical Sciences "L. Sacco", Section of Infectious Diseases, Milan, Italy - University of Milan, Department of Clinical Sciences "L. Sacco", Section of Infectious Diseases, APHP, Hôpital Bichat - Claude Bernard, Laboratoire de Virologie; Paris VII Denis Diderot University - APHP, Hôpital Bichat - Claude Bernard, Laboratoire de Virologie; Paris VII Denis Diderot University, INSERM, U897; University Bordeaux Segalen - INSERM, U897; University Bordeaux Segalen, Paris VII Denis Diderot University; APHP, Hôpital Bichat-Claude Bernard, Service de Maladies infectieuses et Tropicales, Paris, France - Paris VII Denis Diderot University; APHP, Hôpital Bichat-Claude Bernard, Service de Maladies infectieuses et Tropicales, Benard, Antoine, van Sighem, Ard, Taieb, Audrey, Valadas, Emilia, Ruelle, Jean, Soriano, Vicente, Calmy, Alexandra, Balotta, Claudia, Damond, Florence, Brun-Vezinet, Françoise, Chene, Geneviève, and Matheron, Sophie

Published
2011

23. Canine idiopathic pulmonary fibrosis : Clinical disease, biomarkers and histopathological features

Author

Helsingin yliopisto, eläinlääketieteellinen tiedekunta, Helsingfors universitet, veterinärmedicinska fakulteten, University of Helsinki, Faculty of Veterinary Medicine, Kliinisen hevos- ja pieneläinlääketieteen osasto, Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Liège, Belgium, Laurila (os. Heikkilä), Henna, Helsingin yliopisto, eläinlääketieteellinen tiedekunta, Helsingfors universitet, veterinärmedicinska fakulteten, University of Helsinki, Faculty of Veterinary Medicine, Kliinisen hevos- ja pieneläinlääketieteen osasto, Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Liège, Belgium, and Laurila (os. Heikkilä), Henna

Abstract

Canine idiopathic pulmonary fibrosis (CIPF) is a chronic interstitial lung disease of unknown origin mainly affecting West Highland white terriers (WHWT). No curative treatment exists. Differentiating CIPF from other chronic respiratory diseases is difficult. Therefore, a measurable biomarker would be helpful. CIPF shares clinical features with human idiopathic pulmonary fibrosis (IPF), but the histopathological resemblance of the two diseases has been unclear. We described the clinicopathological and diagnostic imaging findings in dogs with CIPF and compared them with those of healthy WHWTs. The most typical clinical signs were cough and exercise intolerance. Inspiratory Velcro crackles were characteristic and an abdominal breathing pattern was often present. Many dogs were hypoxemic. Bronchointerstitial opacity was the most common radiographic finding. In high resolution computed tomography, ground glass opacity was a consistent feature, whereas honeycombing and traction bronchiectasis were less common. Bronchoalveolar lavage fluid (BALF) total cell count was elevated in CIPF and bronchial changes were common. We investigated the serum and BALF concentrations of two potential fibrosis biomarkers, endothelin-1 (ET-1) and procollagen type III amino terminal propeptide (PIIINP) in dogs with CIPF, chronic bronchitis (CB), eosinophilic bronchopneumopathy (EBP) and healthy dogs. Serum ET-1 was higher in dogs with CIPF than in other groups. BALF ET-1 was measurable only in dogs with CIPF. BALF PIIINP was higher in dogs with CIPF than in dogs with CB or healthy dogs, but not different from dogs with EBP. Serum PIIINP was not useful. We defined the histopathological lesions and their distribution in WHWTs with CIPF and compared them with those of human usual interstitial pneumonia (UIP), which is the histopathological pattern of human IPF, and human nonspecific interstitial pneumonia (NSIP), which is an important differential diagnosis of human IPF. A diffuse mature inters, Idiopaattinen keuhkofibroosi (IPF) on krooninen keuhkojen välitilan sairaus, jossa keuhkokudos korvautuu vähitellen sidekudoksella. Sairauden syntysyytä ei tunneta eikä parantavaa hoitoa ole. Ihmisten lisäksi IPF:ään sairastuvat myös koirat. Koiramaailmassa sairaudesta kärsivät erityisesti valkoisetlänsiylämaanterrierit. Väitöskirjan osatyössä I selvitettiin koiran IPF:n taudinkuva sekä sairauteen liittyvät muutokset laboratorio-, röntgen- ja ohutleiketietokonetomografiatutkimuksissa ja keuhkoputkien tähystyksessä. Sairastuneita valkoisialänsiylämaanterrierejä verrattiin terveisiin, samanrotuisiin koiriin. IPF-koirat kärsivät yskästä, heikentyneestä rasituksensietokyvystä ja hapenpuutteesta. Keuhkoauskultaatiossa kuului tarranauharatinaa ja hengitystyyppi oli usein pumppaava. Keuhkojen röntgentutkimuksessa todettiin lisääntyneesti bronkointerstitielliä tiiviyttä. Keuhkojen ohutleiketietokonetomografiassa yleisin muutos oli mattalasitiiviys, hunajakennomuutoksia ja traktionbronkiektasiaa esiintyi harvemmin. Tähystys paljasti keuhkoputkissa muutoksia. Keuhkohuuhtelunesteen kokonaissolumäärä oli noussut. Koiran IPF:n erottaminen muista kroonisista keuhkosairauksista on vaikeaa tavallisilla diagnostisilla menetelmillä. Siksi IPF:stä kertova biologinen merkkiaine, biomarkkeri, olisi tärkeä lisätyökalu. Osatöissä II ja III tutkittiin kahden mahdollisen fibroosibiomarkkerin, endoteeli-1:n (ET-1) ja tyypin III prokollageenin aminoterminaalin propeptidin (PIIINP), käytettävyyttä koiran IPF:n diagnostiikassa. IPF-koirien biomarkkeripitoisuuksia verrattiin terveiden ja kroonista keuhkoputkentulehdusta tai eosinofiilista keuhkotulehdusta sairastavien koirien pitoisuuksiin. Tulokset olivat lupaavia: seerumin ET-1-pitoisuus ja keuhkohuuhtelunesteen PIIINP-pitoisuus auttoivat erottamaan IPF-koirat muista ryhmistä. Taudinkuvaltaan koiran ja ihmisen IPF muistuttavat toisiaan. Mutta entä jos tarkastelu suoritetaan kudostasolla? Osatyössä IV selvitettiin sairauden histopatologiset löy

Published
2015

24. Patient radiation dose ranges for procedures in Universitas Hospital vascular laboratories

Author

H FRIEDRICH-NEL, H FRIEDRICH-NEL, Bloemfontein: Central University of Technology, Free State :Department of Clinical Sciences, H FRIEDRICH-NEL, H FRIEDRICH-NEL, and Bloemfontein: Central University of Technology, Free State :Department of Clinical Sciences

Abstract

Over the past two decades, interventional radiology has been a fast developing field with great advances in technology in the diagnosing and treatment of patients. Interventional radiology procedures are minimally invasive and require little to no hospitalisation time. These procedures are fluoroscopically guided and serial runs are used for documentation, so they have the potential to deliver high doses to patients. Reports about deterministic skin reactions resulting from interventional radiology have become more and more prevalent from the early 1990s. Worldwide concern thus led to legislation for the limitation, justification and optimisation of these doses. Setting of diagnostic reference levels (DRLs) for these procedures is difficult, as they can be complex in nature and are often clinically open-ended. In the case where DRLs were used, they needed to be for a specific locality and had to be refined for the specific circumstances. Patients must be informed of the doses they will be receiving during diagnostic or interventional procedures before consent can be obtained from them. Little information on dose audits was available for South Africa at the time of the study, and it was decided to determine dose ranges at a local level. The research question of this study was: “What radiation doses do patients receive when undergoing vascular, diagnostic and interventional procedures in the interventional suites at a tertiary training hospital in the Free State?” The primary objective was to determine the doses and dose ranges to patients. A secondary objective was to identify specific high dose procedures to individual patients and to the population. A third objective was to investigate the factors influencing these doses. The data of patients who received procedures in two fluoroscopic rooms at the research site were documented over a three-year period. The dose area product (DAP) values were used to calculate skin dose. With the information gathered, dose ranges f

Published
2014

25. ＜Symposium IV＞Cerebral amyloid angiopathy and Alzheimer's disease

Author

Department of Pathology, New York University School of Medicine, Department of Clinical Sciences, Tsukuba University, Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Ghiso, Jorge, Tomidokoro, Yasushi, Revez, Tamas, Frangione, Blas, Rostagno, Agueda, Department of Pathology, New York University School of Medicine, Department of Clinical Sciences, Tsukuba University, Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Ghiso, Jorge, Tomidokoro, Yasushi, Revez, Tamas, Frangione, Blas, and Rostagno, Agueda

Abstract

Cerebral amyloid angiopathy （CAA） is increasingly recognized as a major contributor of Alzheimer’s disease（ AD） pathogenesis. To date, vascular deposits and not parenchymal plaques appear more sensitive predictors of dementia. Amyloid deposition in and around cerebral blood vessels plays a central role in a series of response mechanisms that lead to changes in the integrity of the blood-brain barrier, extravasations of plasma proteins, edema formation, release of inflammatory mediators and matrix metalloproteases which, in turn, produce partial degradation of the basal lamina with the potential to develop hemorrhagic complications. The progressive buildup of amyloid deposits in and around blood vessels chronically limits blood supply and causes focal deprivation of oxygen, triggering a secondary cascade of metabolic events several of which involve the generation of nitrogen and oxygen free radicals with consequent oxidative stress and cell toxicity. Many aspects of CAA in early- and lateonset AD ‒the special preference of Aβ40 to deposit in the vessel walls, the favored vascular compromise associated with many Aβ genetic variants, the puzzling observation that some of these vasculotropic variants solely manifest with recurrent hemorrhagic episodes while others are mainly associated with dementia‒ await clarifi cation. Non-Aβ cerebral amyloidoses reinforce the viewpoint that plaque burden is not indicative of dementia while highlighting the relevance of non-fi brillar lesions and vascular involvement in the disease pathogenesis. The lessons learned from the comparative study of Aβ and non-Aβ cerebral amyloidosis provide new avenues and alternative models to study the role of amyloid in the molecular basis of neurodegeneration.

Published
2010

26. The Adult Life After Childhood Cancer in Scandinavia (ALiCCS) Study: Design and Characteristics

Author

[ 1 ] Aarhus Univ Hosp, Dept Pediat, DK-8200 Aarhus N, Denmark [ 2 ] Danish Canc Soc, Res Ctr, Copenhagen, Denmark [ 3 ] Landspitali Univ Hosp, Childrens Hosp Iceland, Reykjavik, Iceland Organization-Enhanced Name(s) Landspitali National University Hospital [ 4 ] Lund Univ, Dept Clin Sci, Canc Epidemiol, Lund, Sweden [ 5 ] Finnish Canc Registry, FIN-00170 Helsinki, Finland [ 6 ] Jorvi Cent Hosp, Dept Pediat, Espoo, Finland [ 7 ] Univ Iceland, Fac Med, Reykjavik, Iceland [ 8 ] Iceland Canc Registry, Reykjavik, Iceland [ 9 ] Norwegian Canc Registry, Oslo, Norway [ 10 ] Lund Univ, Skane Univ Hosp, Dept Clin Sci Pediat Oncol & Hematol, Lund, Sweden, Department of Pediatrics; Aarhus University Hospital; Aarhus Denmark, Danish Cancer Society Research Center; Copenhagen; Denmark, Department of Clinical Sciences; Lund, Cancer Epidemiology, Lund University; Sweden, Finnish Cancer Registry; Helsinki; Finland, Faculty of Medicine; University of Iceland; Reykjavik Iceland, Norwegian Cancer Registry; Oslo; Norway, Department of Clinical Sciences; Pediatric Oncology and Hematology, Skåne University Hospital, Lund University; Lund Sweden, Asdahl, Peter H., Winther, Jeanette F., Bonnesen, Trine G., De Fine Licht, Sofie, Gudmundsdottir, Thorgerdur, Anderson, Harald, Madanat-Harjuoja, Laura, Tryggvadottir, Laufey, Småstuen, Milada Cvancarova, Holmqvist, Anna Sällfors, Hasle, Henrik, Olsen, Jørgen H., [ 1 ] Aarhus Univ Hosp, Dept Pediat, DK-8200 Aarhus N, Denmark [ 2 ] Danish Canc Soc, Res Ctr, Copenhagen, Denmark [ 3 ] Landspitali Univ Hosp, Childrens Hosp Iceland, Reykjavik, Iceland Organization-Enhanced Name(s) Landspitali National University Hospital [ 4 ] Lund Univ, Dept Clin Sci, Canc Epidemiol, Lund, Sweden [ 5 ] Finnish Canc Registry, FIN-00170 Helsinki, Finland [ 6 ] Jorvi Cent Hosp, Dept Pediat, Espoo, Finland [ 7 ] Univ Iceland, Fac Med, Reykjavik, Iceland [ 8 ] Iceland Canc Registry, Reykjavik, Iceland [ 9 ] Norwegian Canc Registry, Oslo, Norway [ 10 ] Lund Univ, Skane Univ Hosp, Dept Clin Sci Pediat Oncol & Hematol, Lund, Sweden, Department of Pediatrics; Aarhus University Hospital; Aarhus Denmark, Danish Cancer Society Research Center; Copenhagen; Denmark, Department of Clinical Sciences; Lund, Cancer Epidemiology, Lund University; Sweden, Finnish Cancer Registry; Helsinki; Finland, Faculty of Medicine; University of Iceland; Reykjavik Iceland, Norwegian Cancer Registry; Oslo; Norway, Department of Clinical Sciences; Pediatric Oncology and Hematology, Skåne University Hospital, Lund University; Lund Sweden, Asdahl, Peter H., Winther, Jeanette F., Bonnesen, Trine G., De Fine Licht, Sofie, Gudmundsdottir, Thorgerdur, Anderson, Harald, Madanat-Harjuoja, Laura, Tryggvadottir, Laufey, Småstuen, Milada Cvancarova, Holmqvist, Anna Sällfors, Hasle, Henrik, and Olsen, Jørgen H.

Abstract

To access publisher's full text version of this article click on the hyperlink at the bottom of the page, Background. During the last five decades, survival of childhood cancer has increased from 25% to 80%. At the same time, however, it has become evident that survivors experience a broad range of therapy-related late adverse health effects. The aim of the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study is to investigate long-term health consequences of past and current therapies in order to improve follow-up care of survivors and to reduce treatment-related morbidity of future patients. Procedure. Childhood cancer survivors were identified through the five Nordic cancer registries and a comparison cohort was established through random selection of cancer-free individuals from the civil registration systems. A unique personal identification number was used to link between different health registries. Abstraction of treatment information for a subset of survivors allows investigation of the association between the various components of cancer therapy and late occurring comorbidity. Results. The childhood cancer survivor cohort comprises 33,160 1-year survivors and the comparison cohort comprises 212,892 cancer free individuals from the general population. In the childhood cancer survivor cohort, all types of childhood cancer are represented including leukemia (21%), lymphoma (14%), central nervous system tumors (24%), sarcomas (5%), retinoblastoma (3%), and neuroblastoma (4%). Among the survivors, 22% have been followed beyond the age of 40 years. Conclusion. The ALiCCS study constitutes a new large resource for research on late effects of childhood cancers that include all types of childhood malignancies and has followed a large proportion of the survivors well into late adulthood.

27. The Adult Life After Childhood Cancer in Scandinavia (ALiCCS) Study: Design and Characteristics

Author

[ 1 ] Aarhus Univ Hosp, Dept Pediat, DK-8200 Aarhus N, Denmark [ 2 ] Danish Canc Soc, Res Ctr, Copenhagen, Denmark [ 3 ] Landspitali Univ Hosp, Childrens Hosp Iceland, Reykjavik, Iceland Organization-Enhanced Name(s) Landspitali National University Hospital [ 4 ] Lund Univ, Dept Clin Sci, Canc Epidemiol, Lund, Sweden [ 5 ] Finnish Canc Registry, FIN-00170 Helsinki, Finland [ 6 ] Jorvi Cent Hosp, Dept Pediat, Espoo, Finland [ 7 ] Univ Iceland, Fac Med, Reykjavik, Iceland [ 8 ] Iceland Canc Registry, Reykjavik, Iceland [ 9 ] Norwegian Canc Registry, Oslo, Norway [ 10 ] Lund Univ, Skane Univ Hosp, Dept Clin Sci Pediat Oncol & Hematol, Lund, Sweden, Department of Pediatrics; Aarhus University Hospital; Aarhus Denmark, Danish Cancer Society Research Center; Copenhagen; Denmark, Department of Clinical Sciences; Lund, Cancer Epidemiology, Lund University; Sweden, Finnish Cancer Registry; Helsinki; Finland, Faculty of Medicine; University of Iceland; Reykjavik Iceland, Norwegian Cancer Registry; Oslo; Norway, Department of Clinical Sciences; Pediatric Oncology and Hematology, Skåne University Hospital, Lund University; Lund Sweden, Asdahl, Peter H., Winther, Jeanette F., Bonnesen, Trine G., De Fine Licht, Sofie, Gudmundsdottir, Thorgerdur, Anderson, Harald, Madanat-Harjuoja, Laura, Tryggvadottir, Laufey, Småstuen, Milada Cvancarova, Holmqvist, Anna Sällfors, Hasle, Henrik, Olsen, Jørgen H., [ 1 ] Aarhus Univ Hosp, Dept Pediat, DK-8200 Aarhus N, Denmark [ 2 ] Danish Canc Soc, Res Ctr, Copenhagen, Denmark [ 3 ] Landspitali Univ Hosp, Childrens Hosp Iceland, Reykjavik, Iceland Organization-Enhanced Name(s) Landspitali National University Hospital [ 4 ] Lund Univ, Dept Clin Sci, Canc Epidemiol, Lund, Sweden [ 5 ] Finnish Canc Registry, FIN-00170 Helsinki, Finland [ 6 ] Jorvi Cent Hosp, Dept Pediat, Espoo, Finland [ 7 ] Univ Iceland, Fac Med, Reykjavik, Iceland [ 8 ] Iceland Canc Registry, Reykjavik, Iceland [ 9 ] Norwegian Canc Registry, Oslo, Norway [ 10 ] Lund Univ, Skane Univ Hosp, Dept Clin Sci Pediat Oncol & Hematol, Lund, Sweden, Department of Pediatrics; Aarhus University Hospital; Aarhus Denmark, Danish Cancer Society Research Center; Copenhagen; Denmark, Department of Clinical Sciences; Lund, Cancer Epidemiology, Lund University; Sweden, Finnish Cancer Registry; Helsinki; Finland, Faculty of Medicine; University of Iceland; Reykjavik Iceland, Norwegian Cancer Registry; Oslo; Norway, Department of Clinical Sciences; Pediatric Oncology and Hematology, Skåne University Hospital, Lund University; Lund Sweden, Asdahl, Peter H., Winther, Jeanette F., Bonnesen, Trine G., De Fine Licht, Sofie, Gudmundsdottir, Thorgerdur, Anderson, Harald, Madanat-Harjuoja, Laura, Tryggvadottir, Laufey, Småstuen, Milada Cvancarova, Holmqvist, Anna Sällfors, Hasle, Henrik, and Olsen, Jørgen H.

Abstract

To access publisher's full text version of this article click on the hyperlink at the bottom of the page, Background. During the last five decades, survival of childhood cancer has increased from 25% to 80%. At the same time, however, it has become evident that survivors experience a broad range of therapy-related late adverse health effects. The aim of the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study is to investigate long-term health consequences of past and current therapies in order to improve follow-up care of survivors and to reduce treatment-related morbidity of future patients. Procedure. Childhood cancer survivors were identified through the five Nordic cancer registries and a comparison cohort was established through random selection of cancer-free individuals from the civil registration systems. A unique personal identification number was used to link between different health registries. Abstraction of treatment information for a subset of survivors allows investigation of the association between the various components of cancer therapy and late occurring comorbidity. Results. The childhood cancer survivor cohort comprises 33,160 1-year survivors and the comparison cohort comprises 212,892 cancer free individuals from the general population. In the childhood cancer survivor cohort, all types of childhood cancer are represented including leukemia (21%), lymphoma (14%), central nervous system tumors (24%), sarcomas (5%), retinoblastoma (3%), and neuroblastoma (4%). Among the survivors, 22% have been followed beyond the age of 40 years. Conclusion. The ALiCCS study constitutes a new large resource for research on late effects of childhood cancers that include all types of childhood malignancies and has followed a large proportion of the survivors well into late adulthood.

28. The Adult Life After Childhood Cancer in Scandinavia (ALiCCS) Study: Design and Characteristics

Author

[ 1 ] Aarhus Univ Hosp, Dept Pediat, DK-8200 Aarhus N, Denmark [ 2 ] Danish Canc Soc, Res Ctr, Copenhagen, Denmark [ 3 ] Landspitali Univ Hosp, Childrens Hosp Iceland, Reykjavik, Iceland Organization-Enhanced Name(s) Landspitali National University Hospital [ 4 ] Lund Univ, Dept Clin Sci, Canc Epidemiol, Lund, Sweden [ 5 ] Finnish Canc Registry, FIN-00170 Helsinki, Finland [ 6 ] Jorvi Cent Hosp, Dept Pediat, Espoo, Finland [ 7 ] Univ Iceland, Fac Med, Reykjavik, Iceland [ 8 ] Iceland Canc Registry, Reykjavik, Iceland [ 9 ] Norwegian Canc Registry, Oslo, Norway [ 10 ] Lund Univ, Skane Univ Hosp, Dept Clin Sci Pediat Oncol & Hematol, Lund, Sweden, Department of Pediatrics; Aarhus University Hospital; Aarhus Denmark, Danish Cancer Society Research Center; Copenhagen; Denmark, Department of Clinical Sciences; Lund, Cancer Epidemiology, Lund University; Sweden, Finnish Cancer Registry; Helsinki; Finland, Faculty of Medicine; University of Iceland; Reykjavik Iceland, Norwegian Cancer Registry; Oslo; Norway, Department of Clinical Sciences; Pediatric Oncology and Hematology, Skåne University Hospital, Lund University; Lund Sweden, Asdahl, Peter H., Winther, Jeanette F., Bonnesen, Trine G., De Fine Licht, Sofie, Gudmundsdottir, Thorgerdur, Anderson, Harald, Madanat-Harjuoja, Laura, Tryggvadottir, Laufey, Småstuen, Milada Cvancarova, Holmqvist, Anna Sällfors, Hasle, Henrik, Olsen, Jørgen H., [ 1 ] Aarhus Univ Hosp, Dept Pediat, DK-8200 Aarhus N, Denmark [ 2 ] Danish Canc Soc, Res Ctr, Copenhagen, Denmark [ 3 ] Landspitali Univ Hosp, Childrens Hosp Iceland, Reykjavik, Iceland Organization-Enhanced Name(s) Landspitali National University Hospital [ 4 ] Lund Univ, Dept Clin Sci, Canc Epidemiol, Lund, Sweden [ 5 ] Finnish Canc Registry, FIN-00170 Helsinki, Finland [ 6 ] Jorvi Cent Hosp, Dept Pediat, Espoo, Finland [ 7 ] Univ Iceland, Fac Med, Reykjavik, Iceland [ 8 ] Iceland Canc Registry, Reykjavik, Iceland [ 9 ] Norwegian Canc Registry, Oslo, Norway [ 10 ] Lund Univ, Skane Univ Hosp, Dept Clin Sci Pediat Oncol & Hematol, Lund, Sweden, Department of Pediatrics; Aarhus University Hospital; Aarhus Denmark, Danish Cancer Society Research Center; Copenhagen; Denmark, Department of Clinical Sciences; Lund, Cancer Epidemiology, Lund University; Sweden, Finnish Cancer Registry; Helsinki; Finland, Faculty of Medicine; University of Iceland; Reykjavik Iceland, Norwegian Cancer Registry; Oslo; Norway, Department of Clinical Sciences; Pediatric Oncology and Hematology, Skåne University Hospital, Lund University; Lund Sweden, Asdahl, Peter H., Winther, Jeanette F., Bonnesen, Trine G., De Fine Licht, Sofie, Gudmundsdottir, Thorgerdur, Anderson, Harald, Madanat-Harjuoja, Laura, Tryggvadottir, Laufey, Småstuen, Milada Cvancarova, Holmqvist, Anna Sällfors, Hasle, Henrik, and Olsen, Jørgen H.

Abstract

To access publisher's full text version of this article click on the hyperlink at the bottom of the page, Background. During the last five decades, survival of childhood cancer has increased from 25% to 80%. At the same time, however, it has become evident that survivors experience a broad range of therapy-related late adverse health effects. The aim of the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study is to investigate long-term health consequences of past and current therapies in order to improve follow-up care of survivors and to reduce treatment-related morbidity of future patients. Procedure. Childhood cancer survivors were identified through the five Nordic cancer registries and a comparison cohort was established through random selection of cancer-free individuals from the civil registration systems. A unique personal identification number was used to link between different health registries. Abstraction of treatment information for a subset of survivors allows investigation of the association between the various components of cancer therapy and late occurring comorbidity. Results. The childhood cancer survivor cohort comprises 33,160 1-year survivors and the comparison cohort comprises 212,892 cancer free individuals from the general population. In the childhood cancer survivor cohort, all types of childhood cancer are represented including leukemia (21%), lymphoma (14%), central nervous system tumors (24%), sarcomas (5%), retinoblastoma (3%), and neuroblastoma (4%). Among the survivors, 22% have been followed beyond the age of 40 years. Conclusion. The ALiCCS study constitutes a new large resource for research on late effects of childhood cancers that include all types of childhood malignancies and has followed a large proportion of the survivors well into late adulthood.

29. The Adult Life After Childhood Cancer in Scandinavia (ALiCCS) Study: Design and Characteristics

Author

[ 1 ] Aarhus Univ Hosp, Dept Pediat, DK-8200 Aarhus N, Denmark [ 2 ] Danish Canc Soc, Res Ctr, Copenhagen, Denmark [ 3 ] Landspitali Univ Hosp, Childrens Hosp Iceland, Reykjavik, Iceland Organization-Enhanced Name(s) Landspitali National University Hospital [ 4 ] Lund Univ, Dept Clin Sci, Canc Epidemiol, Lund, Sweden [ 5 ] Finnish Canc Registry, FIN-00170 Helsinki, Finland [ 6 ] Jorvi Cent Hosp, Dept Pediat, Espoo, Finland [ 7 ] Univ Iceland, Fac Med, Reykjavik, Iceland [ 8 ] Iceland Canc Registry, Reykjavik, Iceland [ 9 ] Norwegian Canc Registry, Oslo, Norway [ 10 ] Lund Univ, Skane Univ Hosp, Dept Clin Sci Pediat Oncol & Hematol, Lund, Sweden, Department of Pediatrics; Aarhus University Hospital; Aarhus Denmark, Danish Cancer Society Research Center; Copenhagen; Denmark, Department of Clinical Sciences; Lund, Cancer Epidemiology, Lund University; Sweden, Finnish Cancer Registry; Helsinki; Finland, Faculty of Medicine; University of Iceland; Reykjavik Iceland, Norwegian Cancer Registry; Oslo; Norway, Department of Clinical Sciences; Pediatric Oncology and Hematology, Skåne University Hospital, Lund University; Lund Sweden, Asdahl, Peter H., Winther, Jeanette F., Bonnesen, Trine G., De Fine Licht, Sofie, Gudmundsdottir, Thorgerdur, Anderson, Harald, Madanat-Harjuoja, Laura, Tryggvadottir, Laufey, Småstuen, Milada Cvancarova, Holmqvist, Anna Sällfors, Hasle, Henrik, Olsen, Jørgen H., [ 1 ] Aarhus Univ Hosp, Dept Pediat, DK-8200 Aarhus N, Denmark [ 2 ] Danish Canc Soc, Res Ctr, Copenhagen, Denmark [ 3 ] Landspitali Univ Hosp, Childrens Hosp Iceland, Reykjavik, Iceland Organization-Enhanced Name(s) Landspitali National University Hospital [ 4 ] Lund Univ, Dept Clin Sci, Canc Epidemiol, Lund, Sweden [ 5 ] Finnish Canc Registry, FIN-00170 Helsinki, Finland [ 6 ] Jorvi Cent Hosp, Dept Pediat, Espoo, Finland [ 7 ] Univ Iceland, Fac Med, Reykjavik, Iceland [ 8 ] Iceland Canc Registry, Reykjavik, Iceland [ 9 ] Norwegian Canc Registry, Oslo, Norway [ 10 ] Lund Univ, Skane Univ Hosp, Dept Clin Sci Pediat Oncol & Hematol, Lund, Sweden, Department of Pediatrics; Aarhus University Hospital; Aarhus Denmark, Danish Cancer Society Research Center; Copenhagen; Denmark, Department of Clinical Sciences; Lund, Cancer Epidemiology, Lund University; Sweden, Finnish Cancer Registry; Helsinki; Finland, Faculty of Medicine; University of Iceland; Reykjavik Iceland, Norwegian Cancer Registry; Oslo; Norway, Department of Clinical Sciences; Pediatric Oncology and Hematology, Skåne University Hospital, Lund University; Lund Sweden, Asdahl, Peter H., Winther, Jeanette F., Bonnesen, Trine G., De Fine Licht, Sofie, Gudmundsdottir, Thorgerdur, Anderson, Harald, Madanat-Harjuoja, Laura, Tryggvadottir, Laufey, Småstuen, Milada Cvancarova, Holmqvist, Anna Sällfors, Hasle, Henrik, and Olsen, Jørgen H.

Abstract

To access publisher's full text version of this article click on the hyperlink at the bottom of the page, Background. During the last five decades, survival of childhood cancer has increased from 25% to 80%. At the same time, however, it has become evident that survivors experience a broad range of therapy-related late adverse health effects. The aim of the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study is to investigate long-term health consequences of past and current therapies in order to improve follow-up care of survivors and to reduce treatment-related morbidity of future patients. Procedure. Childhood cancer survivors were identified through the five Nordic cancer registries and a comparison cohort was established through random selection of cancer-free individuals from the civil registration systems. A unique personal identification number was used to link between different health registries. Abstraction of treatment information for a subset of survivors allows investigation of the association between the various components of cancer therapy and late occurring comorbidity. Results. The childhood cancer survivor cohort comprises 33,160 1-year survivors and the comparison cohort comprises 212,892 cancer free individuals from the general population. In the childhood cancer survivor cohort, all types of childhood cancer are represented including leukemia (21%), lymphoma (14%), central nervous system tumors (24%), sarcomas (5%), retinoblastoma (3%), and neuroblastoma (4%). Among the survivors, 22% have been followed beyond the age of 40 years. Conclusion. The ALiCCS study constitutes a new large resource for research on late effects of childhood cancers that include all types of childhood malignancies and has followed a large proportion of the survivors well into late adulthood.

30. The Cox model is better than the Fine and Gray model when estimating relative revision risks from arthroplasty register data

Author

1 ] Lund Univ, Dept Clin Sci Lund, Orthoped, Lund, Sweden Show more [ 2 ] Skane Univ Hosp, Lund, Sweden, Department of Clinical Sciences Lund, Orthopedics, Lund University, Ranstam, Jonas, Robertsson, Otto, 1 ] Lund Univ, Dept Clin Sci Lund, Orthoped, Lund, Sweden Show more [ 2 ] Skane Univ Hosp, Lund, Sweden, Department of Clinical Sciences Lund, Orthopedics, Lund University, Ranstam, Jonas, and Robertsson, Otto

Abstract

To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files, Background and purpose - Analysis of the revision-free survival of knee and hip prostheses has traditionally been performed using Kaplan-Meier analysis and Cox regression. The competing risk problem that is related to patients who die during follow-up has recently been increasingly discussed, not least with regard to the problem of choosing a suitable statistical method for the analysis. We compared the results from analyses of Cox models and Fine and Gray models. Methods - We used data simulation based on parameter estimates from the Swedish Knee Arthroplasty Register and assessed hypothetical effects of the studied risk factors. Results - The Cox model provided more adequate results. Interpretation - The parameter estimates from the Fine and Gray model can be misleading if interpreted in terms of relative risk.

31. Higher risk of revision for infection using systemic clindamycin prophylaxis than with cloxacillin

Author

1 ] Lund Univ, Skane Univ Hosp, Swedish Knee Arthroplasty Register, Lund, Sweden [ 2 ] Dept Clin Sci Lund, Orthoped, Lund, Sweden Show more [ 3 ] Skane Univ Hosp, Dept Infect Dis, Lund, Sweden, The Swedish Knee Arthroplasty Register, Lund University, Skåne University Hospital and Department of Clinical Sciences Lund, Orthopedics, Lund, Sweden, Department of Infectious Diseases, Skåne University Hospital, Lund, Sweden, Robertsson, Otto, Thompson, Olof, W-Dahl, Annette, Sundberg, Martin, Lidgren, Lars, Stefánsdóttir, Anna, 1 ] Lund Univ, Skane Univ Hosp, Swedish Knee Arthroplasty Register, Lund, Sweden [ 2 ] Dept Clin Sci Lund, Orthoped, Lund, Sweden Show more [ 3 ] Skane Univ Hosp, Dept Infect Dis, Lund, Sweden, The Swedish Knee Arthroplasty Register, Lund University, Skåne University Hospital and Department of Clinical Sciences Lund, Orthopedics, Lund, Sweden, Department of Infectious Diseases, Skåne University Hospital, Lund, Sweden, Robertsson, Otto, Thompson, Olof, W-Dahl, Annette, Sundberg, Martin, Lidgren, Lars, and Stefánsdóttir, Anna

Abstract

To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files, Background and purpose - Clindamycin has not been compared with other antibiotics for prophylaxis in arthroplasty. Since 2009, the Swedish Knee Arthroplasty Register (SKAR) has been collecting information on the prophylactic antibiotic regime used at every individual operation. In Sweden, when there is allergy to penicillin, clindamycin has been the recommended alternative. We examined whether there were differences in the rate of revision due to infection depending on which antibiotic was used as systemic prophylaxis. Patients and methods - Patients who had a total knee arthroplasty (TKA) performed due to osteoarthritis (OA) during the years 2009-2015 were included in the study. Information on which antibiotic was used was available for 80,018 operations (55,530 patients). Survival statistics were used to calculate the rate of revision due to infection until the end of 2015, comparing the group of patients who received cloxacillin with those who received clindamycin as systemic prophylaxis. Results - Cloxacillin was used in 90% of the cases, clindamycin in 7%, and cephalosporins in 2%. The risk of being revised due to infection was higher when clindamycin was used than when cloxacillin was used (RR =1.5, 95% CI: 1.2-2.0; p = 0.001). There was no significant difference in the revision rate for other causes (p = 0.2). Interpretation - We advise that patients reporting allergic reaction to penicillin should have their allergic history explored. In the absence of a clear history of type-I allergic reaction (e.g. urticaria, anaphylaxis, or bronchospasm), we suggest the use of a third-generation cephalosporin instead of clindamycin as perioperative prophylaxis when undergoing a TKR. No recommendation can be given regarding patients with type-1 allergy.

32. The Cox model is better than the Fine and Gray model when estimating relative revision risks from arthroplasty register data

Author

1 ] Lund Univ, Dept Clin Sci Lund, Orthoped, Lund, Sweden Show more [ 2 ] Skane Univ Hosp, Lund, Sweden, Department of Clinical Sciences Lund, Orthopedics, Lund University, Ranstam, Jonas, Robertsson, Otto, 1 ] Lund Univ, Dept Clin Sci Lund, Orthoped, Lund, Sweden Show more [ 2 ] Skane Univ Hosp, Lund, Sweden, Department of Clinical Sciences Lund, Orthopedics, Lund University, Ranstam, Jonas, and Robertsson, Otto

Abstract

To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files, Background and purpose - Analysis of the revision-free survival of knee and hip prostheses has traditionally been performed using Kaplan-Meier analysis and Cox regression. The competing risk problem that is related to patients who die during follow-up has recently been increasingly discussed, not least with regard to the problem of choosing a suitable statistical method for the analysis. We compared the results from analyses of Cox models and Fine and Gray models. Methods - We used data simulation based on parameter estimates from the Swedish Knee Arthroplasty Register and assessed hypothetical effects of the studied risk factors. Results - The Cox model provided more adequate results. Interpretation - The parameter estimates from the Fine and Gray model can be misleading if interpreted in terms of relative risk.

33. Long-term third-party assessment of results after continent cutaneous diversion with Lundiana pouch

Author

[ 1 ] Lund Univ, Skane Univ Hosp, Dept Urol, Jan Waldenstroms Gata 7, SE-20502 Malmo, Sweden Show the Organization-Enhanced name(s) [ 2 ] Lund Univ, Dept Translat Med, Jan Waldenstroms Gata 7, SE-20502 Malmo, Sweden Show the Organization-Enhanced name(s) [ 3 ] Landspitali Univ Hosp, Dept Urol, Reykjavik, Iceland Show the Organization-Enhanced name(s) [ 4 ] Southern Med Univ, Zhujiang Hosp, Dept Urol, Guangzhou, Guangdong, Peoples R China Show the Organization-Enhanced name(s) [ 5 ] Lund Univ, Dept Clin Sci Lund, Div Oncol & Pathol, Lund, Sweden Show the Organization-Enhanced name(s) [ 6 ] Haukeland Hosp, Dept Urol, Bergen, Norway, Department of Urology; Skåne University Hospital and Department of Translational Medicine; Lund University; Malmö Sweden, Department of Urology; Landspitali University Hospital; Reykjavik Iceland, Department of Urology; Zhujiang Hospital; Southern Medical University; Guangzhou China, Division of Oncology and Pathology; Department of Clinical Sciences Lund; Lund University; Medicon Village; Lund Sweden, Department of Urology; Haukeland Sykehus; Bergen Norway, Liedberg, Fredrik, Gudjonsson, Sigurdur, Xu, Abai, Bendahl, Pär-Ola, Davidsson, Thomas, Månsson, Wiking, [ 1 ] Lund Univ, Skane Univ Hosp, Dept Urol, Jan Waldenstroms Gata 7, SE-20502 Malmo, Sweden Show the Organization-Enhanced name(s) [ 2 ] Lund Univ, Dept Translat Med, Jan Waldenstroms Gata 7, SE-20502 Malmo, Sweden Show the Organization-Enhanced name(s) [ 3 ] Landspitali Univ Hosp, Dept Urol, Reykjavik, Iceland Show the Organization-Enhanced name(s) [ 4 ] Southern Med Univ, Zhujiang Hosp, Dept Urol, Guangzhou, Guangdong, Peoples R China Show the Organization-Enhanced name(s) [ 5 ] Lund Univ, Dept Clin Sci Lund, Div Oncol & Pathol, Lund, Sweden Show the Organization-Enhanced name(s) [ 6 ] Haukeland Hosp, Dept Urol, Bergen, Norway, Department of Urology; Skåne University Hospital and Department of Translational Medicine; Lund University; Malmö Sweden, Department of Urology; Landspitali University Hospital; Reykjavik Iceland, Department of Urology; Zhujiang Hospital; Southern Medical University; Guangzhou China, Division of Oncology and Pathology; Department of Clinical Sciences Lund; Lund University; Medicon Village; Lund Sweden, Department of Urology; Haukeland Sykehus; Bergen Norway, Liedberg, Fredrik, Gudjonsson, Sigurdur, Xu, Abai, Bendahl, Pär-Ola, Davidsson, Thomas, and Månsson, Wiking

Abstract

To access publisher's full text version of this article click on the hyperlink below, OBJECTIVES: To investigate the long-term functional outcomes and complications after continent cutaneous diversion with the Lundiana pouch. PATIENTS AND METHODS: Complications, re-operations, renal function, and continence were ascertained from patient charts. Outcome variables were validated by a second and independent review of the patient files. RESULTS: A complication of Clavien-Dindo grade ≥III, including unscheduled re-admissions, occurred in 45/193 patients (23%) at ≤90 days of surgery. At a median follow-up of 13 years, 105/193 patients (54%) had undergone at least one re-operation, with uretero-intestinal stricture being the most prevalent cause [28 patients (15%)]. Re-operations were more prevalent in patients operated during the first half of the study period than during the second half (2000-2007; 62% vs 47%; P = 0.03), and they were also more frequent in patients who underwent surgery for benign causes than in patients who underwent surgery for malignancy (60% vs 51%; P = 0.04). Continence was achieved in 172/188 patients (91%). In all, 16% of all patients required revisional surgery of the outlet to remain continent with an easily catheterisable pouch or to address stomal stenosis. The mean decrease in estimated glomerular filtration rate was more pronounced in patients with benign indications for urinary diversion than in those with malignancies, even after adjusting for younger age at surgery and longer follow-up in the former group (22 vs 11 mL/min/1.73 m2 ; P < 0.006). A disinterested third-party assessment revealed 10 postoperative complications, 17 re-operations during follow-up, and seven occasions of hospitalisation due to pyelonephritis (included in data above) not recorded at the primary data review. CONCLUSIONS: The Lundiana pouch is associated with a high risk of re-operation, although the functional results are good. Independent review by a third party increased the validity of the outcome data.

34. Development and validation of a lifestyle-based model for colorectal cancer risk prediction: the LiFeCRC score

Author

Amanda J. Cross, Kristin Benjaminsen Borch, Anne Kirstine Eriksen, Elio Riboli, José María Huerta, H. Bas Bueno-de-Mesquita, Giovanna Masala, Núria Sala, Anne Tjønneland, Anika Hüsing, Rudolf Kaaks, Sara Grioni, Anne M. May, Fanny Artaud, Antonia Trichopoulou, Pilar Amiano, Eleni Peppa, Marc J. Gunter, Timothy J. Key, Aurelio Barricarte Gurrea, Jonna Berntsson, Anna Karakatsani, Mazda Jenab, Elisabete Weiderpass, Isabel Drake, Christina C. Dahm, Torkjel M. Sandanger, Bethany Van Guelpen, Robin Reichmann, María José Sánchez, Guri Skeie, Konstantinos K. Tsilidis, Gianluca Severi, Carlotta Sacerdote, Sjoerd G. Elias, José Ramón Quirós, Marie-Christine Boutron-Ruault, Salvatore Panico, Krasimira Aleksandrova, Rosario Tumino, Sophia Harlid, Elom K. Aglago, [Aleksandrova,K, Reichmann,R] Nutrition, Immunity and Metabolism Senior Scientist Group, Department of Nutrition and Gerontology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany. [Aleksandrova,K, Reichmann,R] Institute of Nutritional Science, University of Potsdam, Potsdam, Germany. [Aleksandrova,K] Department of Epidemiological Methods and Etiological Research, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany. [Kaaks,R, Hüsing,A] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Jenab,M, Weiderpass,E, Aglago,EK, Gunter,MJ] International Agency for Research on Cancer, World Health Organization, Lyon, France. [Bueno-de-Mesquita,HB] National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. [Bueno-de-Mesquita,HB, Cross,AJ, Tsilidis,KK, Riboli,E] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [Dahm,CC] Department of Public Health, Aarhus University, Aarhus, Denmark. [Eriksen,AK, Tjønneland,A] Danish Cancer Society Research Center, Copenhagen, Denmark. [Artaud,F, Boutron-Ruault,MC, Severi,G] CESP, Faculté de Medicine, Université Paris-Saclay, Villejuif, France. [Artaud,F, Severi,G] Institut Gustave Roussy, Villejuif, France. [Severi,G] Dipartimento di Statistica, Informatica e Applicazioni 'G. Parenti' (DISIA), University of Florence, Florence, Italy. [Trichopoulou,A, Karakatsani,A, Peppa,E] Hellenic Health Foundation, Athens, Greece. [Karakatsani,A] 2nd Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, 'ATTIKON' University Hospital, Haidari, Greece. [Panico,S] EPIC Centre of Naples, Dipartimento di Medicina Clinica e Chirurgia, University of Naples Federico II, Naples, Italy. [Masala,G] 1Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network – ISPRO, Florence, Italy. [Grioni,S] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. [Sacerdote,C] Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy. [Tumino,R] Cancer Registry and Histopathology Department, Provincial Health Authority (ASP), Ragusa, Italy. [Elias,SG, May,AM] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. [Borch,KB, Sandanger,TM, Skeie,G] Department of Community Medicine, Health Faculty, UiT-the Arctic university of Norway, Tromsø, Norway. [Sánchez,MJ] Escuela Andaluza de Salud Pública (EASP), Granada, Spain. [Sánchez,MJ] Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. [Sánchez,MJ, Huerta,JM, Gurrea,AB, Amiano,P] Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Sánchez,MJ] Universidad de Granada, Granada, Spain. [Huerta,JM] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Sala,N] Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Translational Research Laboratory, Catalan Institute of Oncology (ICO), Barcelona, Spain. [Sala,N] Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. [Gurrea,AB] Navarra Public Health Institute, Pamplona, Spain. [Gurrea,AB] Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. [Quirós,JR] Public Health Directorate, Asturias, Spain. [Amiano,P] Ministry of Health of the Basque Government, Public Health Division of Gipuzkoa, Biodonostia Health Research Institute, Donostia-San Sebastian, Spain. [Berntsson,J] Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden. [Drake,I] Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden. [van Guelpen,B, Harlid,S] Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden. [van Guelpen,B] Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden. [Key,T] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. [Tsilidis,KK] Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece., This work was supported by the German Research Foundation (DFG) (grant AL 1784/3-1), which funded the research position of Dr. Aleksandrova for organizing study conduct and analysis. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum (DKFZ) and Federal Ministry of Education and Research (BMBF) (Germany), Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), Health Research Fund (FIS), Instituto de salud Carlos III PI13/00061 to Granada, PI13/ 01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia (no. 6236), Navarra and Catalonia (Catalan Institute of Oncology – ICO-IDIBELL) (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden), and Cancer Research UK (C864/A14136 to EPIC-Norfolk and C8221/A19170 to EPICOxford), Medical Research Council (MR/N003284/1 and MC-UU_12015/1 to EPIC-Norfolk and MR/M012190/1 to EPIC-Oxford) (United Kingdom). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Open Access funding enabled and organized by Projekt DEAL.

Subjects
Male, Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Probability::Risk::Risk Assessment [Medical Subject Headings], lcsh:Medicine, Cancer prevention, Cohort Studies, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Calibration [Medical Subject Headings], 0302 clinical medicine, Risk Factors, Neoplasias colorrectales, Medicine, 030212 general & internal medicine, Prospective Studies, Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Nutritional Status [Medical Subject Headings], 10. No inequality, Prospective cohort study, 11 Medical and Health Sciences, Framingham Risk Score, Risk screening, Lifestyle behaviour, Risk prediction, Colorectal cancer, Public Health, Global Health, Social Medicine and Epidemiology, General Medicine, Middle Aged, 3. Good health, European Prospective Investigation into Cancer and Nutrition, 030220 oncology & carcinogenesis, Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Prospective Studies [Medical Subject Headings], Female, Risk assessment, Colorectal Neoplasms, Research Article, Cohort study, Estils de vida, Waist, Lifestyles, Nutritional Status, Check Tags::Male [Medical Subject Headings], Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet [Medical Subject Headings], Estil de vida, Risk Assessment, Riesgo, Estilo de vida, 03 medical and health sciences, Càncer colorectal, General & Internal Medicine, Humans, Life Style, business.industry, lcsh:R, Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Probability::Risk [Medical Subject Headings], Technology and Food and Beverages::Food and Beverages::Food::Vegetables [Medical Subject Headings], Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings], Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology, Social::Life Style [Medical Subject Headings], Nomogram, Lifestyle, Diet, Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, Check Tags::Female [Medical Subject Headings], Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Musculoskeletal Physiological Processes::Movement::Motor Activity::Exercise [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], business, Prevención de Enfermedades, Demography
Abstract

Background: Nutrition and lifestyle have been long established as risk factors for colorectal cancer (CRC). Modifiable lifestyle behaviours bear potential to minimize long-term CRC risk; however, translation of lifestyle information into individualized CRC risk assessment has not been implemented. Lifestyle-based risk models may aid the identification of high-risk individuals, guide referral to screening and motivate behaviour change. We therefore developed and validated a lifestyle-based CRC risk prediction algorithm in an asymptomatic European population. Methods: The model was based on data from 255,482 participants in the European Prospective Investigation into Cancer and Nutrition (EPIC) study aged 19 to 70 years who were free of cancer at study baseline (1992–2000) and were followed up to 31 September 2010. The model was validated in a sample comprising 74,403 participants selected among five EPIC centres. Over a median follow-up time of 15 years, there were 3645 and 981 colorectal cancer cases in the derivation and validation samples, respectively. Variable selection algorithms in Cox proportional hazard regression and random survival forest (RSF) were used to identify the best predictors among plausible predictor variables. Measures of discrimination and calibration were calculated in derivation and validation samples. To facilitate model communication, a nomogram and a web-based application were developed. Results: The final selection model included age, waist circumference, height, smoking, alcohol consumption, physical activity, vegetables, dairy products, processed meat, and sugar and confectionary. The risk score demonstrated good discrimination overall and in sex-specific models. Harrell’s C-index was 0.710 in the derivation cohort and 0.714 in the validation cohort. The model was well calibrated and showed strong agreement between predicted and observed risk. Random survival forest analysis suggested high model robustness. Beyond age, lifestyle data led to improved model performance overall (continuous net reclassification improvement = 0.307 (95% CI 0.264–0.352)), and especially for young individuals below 45 years (continuous net reclassification improvement = 0.364 (95% CI 0.084–0.575)). Conclusions: LiFeCRC score based on age and lifestyle data accurately identifies individuals at risk for incident colorectal cancer in European populations and could contribute to improved prevention through motivating lifestyle change at an individual level., German Research Foundation (DFG) AL 1784/3-1, European Commission European Commission Joint Research Centre, International Agency for Research on Cancer, Danish Cancer Society, Ligue Contre le Cancer (France), Institut Gustave Roussy (France), Mutuelle Generale de l'Education Nationale (France), Institut National de la Sante et de la Recherche Medicale (Inserm), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum (DKFZ) (Germany), Federal Ministry of Education & Research (BMBF), Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro (AIRC), Consiglio Nazionale delle Ricerche (CNR), Netherlands Government, World Cancer Research Fund International (WCRF), Instituto de Salud Carlos III PI13/00061 PI13/01162, Junta de Andalucia, Regional Government of Asturias (Spain), Regional Government of Basque Country (Spain), Regional Government of Murcia (Spain) 6236, Regional Government of Navarra (Spain), Regional Government of Catalonia (Catalan Institute of Oncology -ICO-IDIBELL) (Spain), Swedish Cancer Society, Swedish Research Council, County Council of Skane (Sweden), County Council of Vasterbotten (Sweden), Cancer Research UK C864/A14136 C8221/A19170, UK Research & Innovation (UKRI) Medical Research Council UK (MRC) MR/N003284/1 MC-UU_12015/1 MR/M012190/1, Projekt DEAL

Published
2021
Full Text
View/download PDF

35. Half of the patients with subepithelial tumours present borderline or pathologic anxiety-distress and carcinophobia: multicentre cohort study

Author

Francesc Bas-Cutrina, Anna Casellas-Grau, Sebasti� Videla, Carme Loras, Xavi Andújar, Francisco Luis Gil, Maica Galán, Fernando Fernández-Aranda, Jo�o Carmezim, Joan B. Gornals, [Bas-Cutrina F] Endoscopy Unit. Department of Digestive Diseases. Hospital Universitari de Bellvitge. Barcelona, Spain. Bellvitge Biomedical Research Institute (IDIBELL). Barcelona, Spain. Department of Clinical Sciences. School of Medicine and Health Sciences. Universitat de Barcelona (UB). Barcelona, Spain. Digestive Diseases Unit. Hospital General de Granollers. Granollers, Spain. [Casellas-Grau A] Psycho-oncology Service. Institut Català d’Oncologia (ICO). L’Hospitalet de Llobregat, Barcelona. Spain. Department of Psychology. School of Education, Translation, Sports and Psychology. Universitat de Vic – Universitat Central de Catalunya (UVic-UCC). Vic, Barcelona. Spain. [Videla S] Bellvitge Biomedical Research Institute (IDIBELL). Barcelona, Spain. Department of Clinical Sciences. School of Medicine and Health Sciences. Universitat de Barcelona (UB). Barcelona, Spain. Clinical Research Support Unit. Hospital Universitari de Bellvitge. L´Hospitalet de Llobregat, Barcelona. Spain. [Loras C, Andújar X] Endoscopy Unit. Department of Digestive Diseases. Hospital Universitari Mútua de Terrassa. Terrassa, Barcelona. Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). Instituto de Salud Carlos III. Madrid, Spain. [Gil FL] Psycho-oncology Service. Institut Català d’Oncologia (ICO). L’Hospitalet de Llobregat, Barcelona. Spain. Tecnocampus Mataró-Maresme Foundation. Universitat Pompeu Fabra (UPF). Barcelona, Spain. [Galán M] Department of Clinical Sciences. School of Medicine and Health Sciences. Universitat de Barcelona (UB). Barcelona, Spain. Department of Medical Oncology. Institut Català d’Oncologia (ICO). L’Hospitalet de Llobregat, Barcelona. Spain. [Fernández-Aranda F] Bellvitge Biomedical Research Institute (IDIBELL). Barcelona, Spain. Department of Clinical Sciences. School of Medicine and Health Sciences. Universitat de Barcelona (UB). Barcelona, Spain. Eating Disorders Unit. Department of Psychiatry. Hospital Universitari de Bellvitge. L´Hospitalet de Llobregat, Barcelona. Spain. Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn). Instituto de Salud Carlos III. Madrid, Spain. [Carmezim J] Bellvitge Biomedical Research Institute (IDIBELL). Barcelona, Spain. , [Gornals JB] Endoscopy Unit. Department of Digestive Diseases. Hospital Universitari de Bellvitge. Barcelona, Spain. Bellvitge Biomedical Research Institute (IDIBELL). Barcelona, Spain. Department of Clinical Sciences. School of Medicine and Health Sciences. Universitat de Barcelona (UB). Barcelona, Spain. Faculty of Health Sciences. Universitat Oberta de Catalunya (UOC). Barcelona, Spain, and Hospital General de Granollers

Subjects
Mental Disorders::Anxiety Disorders [PSYCHIATRY AND PSYCHOLOGY], Ansietat, trastornos mentales::trastornos de ansiedad [PSIQUIATRÍA Y PSICOLOGÍA], Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms [DISEASES], neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales [ENFERMEDADES], Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Cohort Studies [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de cohortes [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Gastroenterology, General Medicine, Avaluació, Aparell digestiu - Càncer
Abstract

Subepithelial tumors; Carcinophobia; Multicenter cohort study Tumores subepiteliales; Carcinofobia; Estudio de cohorte multicéntrico Tumors subepitelials; Carcinofòbia; Estudi de cohorts multicèntric Background and aims: Minor nonspecific gastrointestinal subepithelial lesions (usually defined by the term 'tumor') are usually associated with a malignant illness and cancer. The aim of this study was to assess anxiety-distress and carcinophobia in patients referred to specialized monographic outpatient clinics for evaluation and treatment of this type of lesion. Methods: Prospective, multicenter, cohort study. Specific self-reported questionnaires were used to report threatening life-experiences and to assess levels of distress (The Hospital Anxiety and Depression Scale) and cancer-related worries (The Cancer Worry Scale). Results: Forty participants were included and analyzed at baseline. Pathologic and borderline anxiety were detected in 13% (5/40, 95%CI: 4-27%) and 35% (14/40, 95%CI: 21-52%) of participants, respectively, whereas, cancer-related worries (moderate to very high) were observed in 48% (19/40, 95%CI: 32-64%) of participants. Pathologic global distress was identified in 25% (10/40, 95%CI: 13-42%) of subjects. Higher educational level (university studies), a lack of lifetime psychiatric comorbidity and a lack of family history of cancer were associated with less anxiety, global distress and carcinophobia. Conclusions: Almost half of the patients diagnosed with a minor nonspecific gastrointestinal subepithelial lesion presented anxiety-distress and/or carcinophobia. Specific associations with anxiety-distress reaction and fears were detected.

Published
2022
Full Text
View/download PDF

36. Effectiveness of a telephone-based intervention for smoking cessation in patients with severe mental disorders: study protocol for a randomized controlled trial

Author

Institut Català de la Salut, [Ballbè M] Tobacco Control Unit, Cancer Control and Prevention Program, Institut Català d'Oncologia-ICO, L'Hospitalet de Llobregat, Barcelona, Spain. Cancer Control and Prevention Group, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. Addictions Unit, Institute of Neurosciences, Hospital Clínic de Barcelona, Barcelona, Spain. [Martínez C] Tobacco Control Unit, Cancer Control and Prevention Program, Institut Català d'Oncologia-ICO, L'Hospitalet de Llobregat, Barcelona, Spain. Cancer Control and Prevention Group, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. Medicine and Health Sciences School, Universitat Internacional de Catalunya, Sant Cugat del Valles, Barcelona, Spain. Department of Clinical Sciences, School of Medicine, Universitat de Barcelona, L'Hospitalet del Llobregat, Barcelona, Spain. [Feliu A] Tobacco Control Unit, Cancer Control and Prevention Program, Institut Català d'Oncologia-ICO, L'Hospitalet de Llobregat, Barcelona, Spain. Cancer Control and Prevention Group, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. Department of Clinical Sciences, School of Medicine, Universitat de Barcelona, L'Hospitalet del Llobregat, Barcelona, Spain. [Torres N] 061 CatSalut Respon, Sistema d'Emergències Mèdiques, L'Hospitalet de Llobregat, Barcelona, Spain. [Nieva G] Servei de Psiquiatria, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d’Hebron Institut de Recerca, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. [Pinet C] Addictive Behaviors Unit, Psychiatry Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Bruguera E] Servei de Psiquiatria, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d’Hebron Institut de Recerca, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., and Hospital Universitari Vall d'Hebron

Subjects
Other subheadings::/methods [Other subheadings], Instalaciones para Atención de Salud, Recursos Humanos y Servicios::Servicios de Salud::Servicios Médicos de Urgencia::Líneas Directas [ATENCIÓN DE SALUD], Assessorament psicològic per telèfon, Tabaquisme - Tractament, personas::personas con discapacidad::personas con enfermedad mental [DENOMINACIONES DE GRUPOS], Health Care Facilities, Manpower, and Services::Health Services::Emergency Medical Services::Hotlines [HEALTH CARE], Otros calificadores::/métodos [Otros calificadores], Study Characteristics::Clinical Study::Clinical Trial [PUBLICATION CHARACTERISTICS], Behavior and Behavior Mechanisms::Behavior::Health Behavior::Smoking Cessation [PSYCHIATRY AND PSYCHOLOGY], Malalties mentals, Características de los Estudios::Estudio Clínico::Ensayo Clínico [CARACTERÍSTICAS DE PUBLICACIONES], Persons::Disabled Persons::Mentally Ill Persons [NAMED GROUPS], conducta y mecanismos de la conducta::conducta::conducta sanitaria::cese del hábito de fumar [PSIQUIATRÍA Y PSICOLOGÍA], Assaigs clínics
Published
2021

37. Physical activity and risks of breast and colorectal cancer : a Mendelian randomisation analysis

Author

Michael O. Woods, Fränzel J.B. van Duijnhoven, Tilman Kühn, Graham G. Giles, Temitope O. Keku, Konstantinos K. Tsilidis, Andrew T. Chan, Mingyang Song, Michael Hoffmeister, Gad Rennert, Tabitha A. Harrison, Anna H. Wu, Kenneth Offit, Mark A. Jenkins, Elizabeth A Platz, Sabina Sieri, Noralane M Lindor, John D. Potter, D Timothy Bishop, Barbara L. Banbury, Anne M. May, Sonja I. Berndt, José María Huerta, Antonia Trichopoulou, Paul D.P. Pharoah, Niki Dimou, Christopher I. Li, Roger L. Milne, Marc J. Gunter, Hermann Brenner, Martha L. Slattery, Catherine M. Tangen, Gianluca Severi, Richard M. Martin, Nabila Kazmi, Ruth C. Travis, Sanford D. Markowitz, Jeroen R. Huyghe, Heather Hampel, Ulrike Peters, John L. Hopper, Brigid M. Lynch, Krasimira Aleksandrova, Alicja Wolk, Merete Ellingjord-Dale, Li Li, Bethany Van Guelpen, Sergi Castellví-Bel, Edward Giovannucci, Steven J Gallinger, Annika Lindblom, Cornelia M. Ulrich, Stephen B. Gruber, Stephanie L. Schmit, Jenny Chang-Claude, Lorena Moreno, Victor Moreno, Nikos Papadimitriou, Stephen N. Thibodeau, Elio Riboli, Sophia Harlid, Polly A. Newcomb, Pavel Vodicka, Demetrius Albanes, Bas Bueno-de-Mesquita, Maria J. Sánchez, Sarah J Lewis, Timothy Robinson, Daniel D Buchanan, Loic Le Marchand, Carlo La Vecchia, Robert E Schoen, Neil Murphy, Giovanna Masala, Evelyn M. Monninkhof, Jane C. Figueiredo, Andrea Gsur, Jochen Hampe, Vittorio Perduca, Li Hsu, Emily White, Peter T. Campbell, School of Public Health - Department of Epidemiology and Biostatistics, Imperial College London, University of Bristol [Bristol], National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH), Department of Epidemiology, German Institute of Human Nutrition, Division of Cancer Epidemiology and Genetics [Bethesda, MD, États-Unis], National Institutes of Health [Bethesda] (NIH)-National Institutes of Health [Bethesda] (NIH), Division of Clinical Epidemiology and Aging Research, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment [Bilthoven] (RIVM), The Cancer, Ageing and Somatic Mutation Programme [Cambridgeshire, UK], The Wellcome Trust Sanger Institute [Cambridge], Division of Cancer Epidemiology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital [Toronto, Canada] (MSH), University of Melbourne, Harvard School of Public Health, Department of Internal Medicine, Epidemiology, Human Genetics, University of Michigan [Ann Arbor], University of Michigan System-University of Michigan System, Medical Department 1 [Dresden, Germany], Technische Universität Dresden = Dresden University of Technology (TU Dresden), Ohio State University [Columbus] (OSU), FESTO, Universität Stuttgart [Stuttgart], Centre for MEGA Epidemiology, The University of Melbourne, Victoria, Australia, CIBER de Epidemiología y Salud Pública (CIBERESP), Department of Medical Genetics, HMNC Brain Health, Department of Clinical Sciences and Community Health [Milan, Italy], Università degli Studi di Milano [Milano] (UNIMI), University of Hawai‘i [Mānoa] (UHM), Chinese Center for Disease Control and Prevention, Department of Clinical Genetics, Karolinska University Hospital [Stockholm], Mayo Clinic, Case Western Reserve University [Cleveland], Cancer Risk Factors and LifeStyle Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Julius Center for Health Sciences and Primary Care, University Medical Center [Utrecht], Cancer Epidemiology Centre, Cancer Council Victoria, Biomedical Research Centre Network for Rare Diseases, CIBER de Enfermedades Raras (CIBERER), Memorial Sloane Kettering Cancer Center [New York], Mathématiques Appliquées Paris 5 (MAP5 - UMR 8145), Université Paris Descartes - Paris 5 (UPD5)-Institut National des Sciences Mathématiques et de leurs Interactions (INSMI)-Centre National de la Recherche Scientifique (CNRS), Department of Oncology, University of Cambridge [UK] (CAM), Johns Hopkins Bloomberg School of Public Health [Baltimore], Johns Hopkins University (JHU), Department of Community Medicine and Epidemiology, CHS National Cancer Control Center, School of Public Health [London, UK] (Faculty of Medicine), Andalusian School of Public Health [Granada], Istituto Nazionale dei Tumori, Fred Hutchinson Cancer Research Center [Seattle] (FHCRC), Mayo Clinic [Rochester], University of Oxford [Oxford], WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Dept of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School [Athens]-University of Athens Medical School [Athens], Helmholtz Centre for Ocean Research [Kiel] (GEOMAR), Department of Medical Biosciences and Pathology, Umeå University, Institute of Experimental Medicine, Czech Academy of Sciences [Prague] (CAS), Karolinska Institutet [Stockholm], Nutrition and Metabolism Section, International Agency for Research on Cancer, [Papadimitriou,N, Dimou,N, Gunter,MJ, Murphy,N] Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France. [Tsilidis,KK] Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. [Tsilidis,KK, Ellingjord-Dale,M, Riboli,E] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [Banbury,B, Harrison,TA, Hsu,L, Huyghe,JR, Li,CI, Newcomb,PA, Potter,JD, White,E, Peters,U] Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. [Martin,RM, Kazmi,N] MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. [Martin,RM, Lewis,SJ, Robinson,TM] Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, UK. [Martin,RM] National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and the University of Bristol, Bristol, UK. [Albanes,D, Berndt,SI] Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MA, USA. [Aleksandrova,K] German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany. [Bishop,DT] Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK. [Brenner,H, Hoffmeister,M] Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Brenner,H] Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany. [Brenner,H] German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. [Buchanan,DD, Giles,GG, Hopper,JL, Jenkins,MA, Lynch,B, Milne,R] Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia. [Buchanan,DD] Colorectal Oncogenomics Group, Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, VIC, Australia. [Buchanan,DD] Genetic Medicine and Family Cancer Clinic, The Royal Melbourne Hospital, Parkville, VIC, Australia [Bueno-de-Mesquita,B] Former senior scientist, Dept. for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), BA Bilthoven, Netherlands. [Bueno-de-Mesquita,B] Former associate professor, Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, Netherlands. [Bueno-de-Mesquita,B] ormer visiting professor, Dept. of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, St Mary’s Campus, Norfolk Place, London, London, UK. [Bueno-de-Mesquita,B] Former academic Icon / visiting professor, Dept. of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Pantai Valley, Kuala Lumpur, Malaysia. [Campbell,PT] Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, GA, USA. [Castellví-Bel,S, Moreno,L] Gastroenterology Department, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain. [Chan,AT, Song,M] Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. [Chan,AT, Song,M] Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. [Chang-Claude,J, Kühn,T] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Chang-Claude,J] University Medical Centre Hamburg-Eppendorf, University Cancer Centre Hamburg (UCCH), Hamburg, Germany. [Figueiredo,JC] Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. [Figueiredo,JC] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. [Gallinger,SJ] Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. [Giles,GG, Milne,R] Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia. [Giovannucci,E, Song,M] Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA. [Giovannucci,E, Song,M] Department of Nutrition, T.H. H, Chan School of Public Health, Boston, MA, USA. [Giovannucci,E] Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA. [Gruber,SB, Schmit,SL] Department of Preventive Medicine, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. [Gsur,A] Institute of Cancer Research, Department of Medicine I, Medical University Vienna, Vienna, Austria. [Hampe,J] Department of Medicine I, University Hospital Dresden, Technische Universität Dresden (TU Dresden), Dresden, Germany. [Hampel,H] Division of Human Genetics, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. [Harlid,S] Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden. [Hopper,JL] Department of Epidemiology, School of Public Health and Institute of Health and Environment, Seoul National University, Seoul, South Korea. [Hsu,L] Department of Biostatistics, University of Washington, Seattle, WA, USA. [Huerta,JM, Moreno,V, Sánchez,MJ] CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Huerta,JM] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Keku,TO] Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, NC, USA. [La Vecchia,C, Trichopoulou,A] Hellenic Health Foundation, Athens, Greece. [La Vecchia,C] Dept. of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy. [Le Marchand,L] University of Hawaii Cancer Center, Honolulu, HI, USA. [Li,L] Department of Family Medicine, University of Virginia, Charlottesville, VA, USA. [Lindblom,A] Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. [Lindblom,A] Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. [Lindor,NM] Department of Health Science Research, Mayo Clinic, Scottsdale, AZ, USA. [Lynch,B] Physical Activity Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. [Markowitz,SD] Departments of Medicine and Genetics, Case Comprehensive Cancer Center, Case Western Reserve University, and University Hospitals of Cleveland, Cleveland, OH, USA. [Masala,G] Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy. [May,AM, Monninkhof,E] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, GA UTRECHT, Netherlands. [Milne,R] Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, VIC, Australia. [Moreno,V] Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. [Moreno,V] Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain. [Newcomb,PA] School of Public Health, University of Washington, Seattle, WA, USA. [Offit,K] Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. [Offit,K] Department of Medicine, Weill Cornell Medical College, New York, NY, USA. [Perduca,V, Severi,G] CESP, Fac. de médecine - Univ. ParisSud, Fac. de médecine - UVSQ I, Université Paris-Saclay, Villejuif, France. [Perduca,V, Severi,G] Gustave Roussy, Villejuif, France. [Perduca,V] Laboratoire de Mathématiques Appliquées MAP5 (UMR CNRS 8145), Université Paris Descartes, Paris, France. [Pharoah,PDP] Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. [Platz,EA] Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. [Rennert,G] Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel. [Rennert,G] 7Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. [Rennert,G] Clalit National Cancer Control Center, Haifa, Israel. [Sánchez,MJ] Andalusian School of Public Health, Biomedical Research Institute ibs.GRANADA, University of Granada, Granada, Spain. [Schmit,SL] Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. [Schoen,RE] Department of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. [Sieri,S] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Slattery,ML] Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA. [Tangen,CM] SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. [Thibodeau,SN] Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. [Travis,RC] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. [Ulrich,CM] Huntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA. [van Duijnhoven,FJB] Division of Human Nutrition, Wageningen University and Research, Wageningen, Netherlands. [Van Guelpen,B] Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden. [Van Guelpen,B] Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden. [Vodicka,P] Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. [Vodicka,P] Faculty of Medicine and Biomedical Center in Pilsen, Charles University, Pilsen, Czech Republic. [Vodicka,P] Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic. [White,E, Peters,U] Department of Epidemiology, University of Washington, Seattle, WA, USA. [Wolk,A] Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. [Woods,MO] Memorial University of Newfoundland, Discipline of Genetics, St. John’s, Canada. [Wu,AH] University of Southern California, Preventative Medicine, Los Angeles, CA, USA., This work was supported by the National Cancer Institute, the International Agency for Research on Cancer and a Cancer Research UK program grant (C18281/A19169 to RMM, SJL & NK). RMM was supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The funding sources for BCAC, CCFR, GECCO, and CORECT consortia are presented in detail in the appendix in the Supplementary material., Tsilidis, Konstantinos K [0000-0002-8452-8472], Martin, Richard M [0000-0002-7992-7719], Lewis, Sarah J [0000-0003-4311-6890], Robinson, Timothy M [0000-0003-0933-646X], Timothy Bishop, D [0000-0002-8752-8785], Buchanan, Daniel D [0000-0003-2225-6675], Chan, Andrew T [0000-0001-7284-6767], Giles, Graham G [0000-0003-4946-9099], Gsur, Andrea [0000-0002-9795-1528], Hampe, Jochen [0000-0002-2421-6127], Hampel, Heather [0000-0001-7558-9794], Harlid, Sophia [0000-0001-8540-6891], Harrison, Tabitha A [0000-0002-4173-7530], María Huerta, José [0000-0002-9637-3869], Huyghe, Jeroen R [0000-0001-6027-9806], Jenkins, Mark A [0000-0002-8964-6160], La Vecchia, Carlo [0000-0003-1441-897X], Masala, Giovanna [0000-0002-5758-9069], Milne, Roger [0000-0001-5764-7268], Moreno, Victor [0000-0002-2818-5487], Newcomb, Polly A [0000-0001-8786-0043], Perduca, Vittorio [0000-0003-0339-0473], Pharoah, Paul D P [0000-0001-8494-732X], Potter, John D [0000-0001-5439-1500], Rennert, Gad [0000-0002-8512-068X], Riboli, Elio [0000-0001-6795-6080], Schmit, Stephanie L [0000-0001-5931-1194], Schoen, Robert E [0000-0001-7153-2766], Van Guelpen, Bethany [0000-0002-9692-101X], Wolk, Alicja [0000-0001-7387-6845], Peters, Ulrike [0000-0001-5666-9318], Murphy, Neil [0000-0003-3347-8249], Apollo - University of Cambridge Repository, Tsilidis, Konstantinos K. [0000-0002-8452-8472], Martin, Richard M. [0000-0002-7992-7719], Lewis, Sarah J. [0000-0003-4311-6890], Timothy Bishop, D. [0000-0002-8752-8785], Buchanan, Daniel D. [0000-0003-2225-6675], Chan, Andrew T. [0000-0001-7284-6767], Giles, Graham G. [0000-0003-4946-9099], Harrison, Tabitha A. [0000-0002-4173-7530], Huyghe, Jeroen R. [0000-0001-6027-9806], Jenkins, Mark A. [0000-0002-8964-6160], Newcomb, Polly A. [0000-0001-8786-0043], Pharoah, Paul D. P. [0000-0001-8494-732X], Potter, John D. [0000-0001-5439-1500], Schmit, Stephanie L. [0000-0001-5931-1194], Schoen, Robert E. [0000-0001-7153-2766], and Pharoah, Paul DP [0000-0001-8494-732X]

Subjects
Oncology, Epidemiology, Colorectal cancer, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Accelerometry [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Molecular Epidemiology::Mendelian Randomization Analysis [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Breast cancer, Epidemiology of cancer, Accelerometry, Odds Ratio, lcsh:Science, skin and connective tissue diseases, Cancer genetics, ComputingMilieux_MISCELLANEOUS, Cancer, 0303 health sciences, Biobank, 3. Good health, 030220 oncology & carcinogenesis, ICEP, Factores de riesgo, medicine.medical_specialty, Science, 631/67/2324, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms::Colorectal Neoplasms, Hereditary Nonpolyposis [Medical Subject Headings], Breast Neoplasms/genetics, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Càncer colorectal, Anthropology, Education, Sociology and Social Phenomena::Human Activities::Exercise [Medical Subject Headings], Humans, Epidemiologia, Exercise, VLAG, Cancer och onkologi, 45, 631/67/1347, Odds ratio, Mendelian Randomization Analysis, medicine.disease, Colorectal Neoplasms/genetics, 030104 developmental biology, Analyses, Risk factors, Check Tags::Female [Medical Subject Headings], Cancer and Oncology, lcsh:Q, Breast neoplasms, 0301 basic medicine, 631/67/1504/1885, Nutrition and Disease, General Physics and Astronomy, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Risk Factors, Neoplasias colorrectales, Voeding en Ziekte, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Odds Ratio [Medical Subject Headings], Multidisciplinary, article, Public Health, Global Health, Social Medicine and Epidemiology, Polymorphism, Single Nucleotide/genetics, Ejercicio físico, Neoplasias de la mama, Female, Colorectal Neoplasms, 631/67, 141, Breast Neoplasms, 45/23, Polymorphism, Single Nucleotide, Colorectal neoplasms, Càncer de mama, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Susceptibility::Genetic Predisposition to Disease [Medical Subject Headings], Cancer epidemiology, 631/67/68, Internal medicine, Mendelian randomization, medicine, Journal Article, Life Science, Genetic Predisposition to Disease, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], 030304 developmental biology, Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic::Polymorphism, Single Nucleotide [Medical Subject Headings], business.industry, General Chemistry, Physical fitness, Confidence interval, Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Condició física
Abstract

Physical activity has been associated with lower risks of breast and colorectal cancer in epidemiological studies; however, it is unknown if these associations are causal or confounded. In two-sample Mendelian randomisation analyses, using summary genetic data from the UK Biobank and GWA consortia, we found that a one standard deviation increment in average acceleration was associated with lower risks of breast cancer (odds ratio [OR]: 0.51, 95% confidence interval [CI]: 0.27 to 0.98, P-value = 0.04) and colorectal cancer (OR: 0.66, 95% CI: 0.48 to 0.90, P-value = 0.01). We found similar magnitude inverse associations for estrogen positive (ER+ve) breast cancer and for colon cancer. Our results support a potentially causal relationship between higher physical activity levels and lower risks of breast cancer and colorectal cancer. Based on these data, the promotion of physical activity is probably an effective strategy in the primary prevention of these commonly diagnosed cancers., United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Cancer Institute (NCI), International Agency for Research on Cancer, Cancer Research UK C18281/A19169, National Institute for Health Research (NIHR)

Published
2020
Full Text
View/download PDF

39. Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and risk of in situ breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort

Author

Christina C. Dahm, Marc J. Gunter, Carlotta Sacerdote, Carmen Santiuste, Sabine Rohrmann, Merete Ellingjord-Dale, Cecilie Kyrø, Anika Hüsing, Renée T. Fortner, Eva Ardanaz, Antonia Trichopoulou, María Dolores López, Claudia Agnoli, Elisabete Weiderpass, Virginia Menéndez, Rudolf Kaaks, Signe Borgquist, Marina Kvaskoff, Patrick Arveux, Anne Tjønneland, Carlo La Vecchia, Helene Tilma Vistisen, Marije F. Bakker, Antonio Agudo, María José Sánchez, Agnès Fournier, Laure Dossus, Kay-Tee Khaw, Timothy J. Key, Guri Skeie, Eleni Peppa, Rosario Tumino, Elio Riboli, Salma Butt, Carla H. van Gils, Nena Karavasiloglou, Kostantinos K. Tsilidis, Tilman Kühn, Giovanna Masala, Inge Huybrechts, Matthias B. Schulze, Domenico Palli, Anna Karakatsani, Jenny Chang-Claude, Salvatore Panico, Apollo - University of Cambridge Repository, [Karavasiloglou,N, Rohrmann,S] Division of Chronic Disease Epidemiology, Institute for Epidemiology, Biostatistics and Prevention, University of Zurich, Zurich, Switzerland. [Karavasiloglou,N, Rohrmann,S] Cancer Registry Zurich and Zug, University Hospital Zurich, Zurich, Switzerland. [Karavasiloglou,N, Hüsing,A, Turzanski Fortner,R, Chang-Claude,J, Kaaks,R, Kühn,T] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Masala,G, Palli,D] Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy. [van Gils,CH, Bakker,MF] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. [Huybrechts,I, Weiderpass,E, Dossus,L] International Agency for Research on Cancer, Lyon, France. [Weiderpas,E, Skeie,G] Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. [Arveux,P, Fournier,A, Kvaskoff,M] CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France. [Arveux,P, Kvaskoff,M] Gustave Roussy, Villejuif, France. [Arveux,P] Breast and Gynaecologic Cancer Registry of Côte d’Or, Georges-François Leclerc Cancer Centre, UNICANCER, Dijon, France. [Tjønneland,A] Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. [Tjønneland,A, Kyrø,C] Danish Cancer Society Research Center, Copenhagen, Denmark. [Dahm,CC, Vistisen,HT] Department of Public Health, Aarhus University, Aarhus, Denmark. [Sánchez,MJ] Andalusian School of Public Health (EASP), Granada, Spain. [Sánchez,MJ] Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain. [Sánchez,MJ, Chirlaque López,MD, Santiuste,C, Ardanaz,E] CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. [Sánchez,MJ] Universidad de Granada, Granada, Spain. [Chirlaque López,MD, Santiuste,C] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Chirlaque López,MD] Department of Health and Social Sciences, Murcia University, Murcia, Spain. [Ardanaz,E] Navarra Public Health Institute, Pamplona, Spain. [Ardanaz,E] IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. [Menéndez,V] Public Health Directorate, Asturias, Spain. [Agudo,A] Unit of Nutrition and Cancer, Catalan Institute of Oncology - ICO, Nutrition and Cancer Group, Bellvitge Biomedical Research Institute - IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. [Trichopoulou,A, Karakatsani,A, La Vecchia,C, Peppa,E] Hellenic Health Foundation, Athens, Greece. [Karakatsani,A] 2nd Pulmonary Medicine Department, School of Medicine, 'ATTIKON' University Hospital, National and Kapodistrian University of Athens, Haidari, Greece. [La Vecchia,C] Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy. [Agnoli,C] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Panico,S] Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy. [Tumino,R] Cancer Registry and Histopathology Department, Azienda Sanitaria Provinciale (ASP), Ragusa, Italy. [Sacerdote,C] Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy. [Butt,ST] Department of Clinical Sciences, Lund University, Malmö, Sweden. [Butt,ST] Department of Surgery, Skåne University Hospital, Malmö, Sweden. [Borgquist,S] Department of Oncology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark. [Borgquist,S] Division of Oncology and Pathology, Clinical Sciences, Lund University, Lund, Sweden. [Skeie,G] Nutritional Epidemiology Group, School of Food Science and Nutrition, University of Leeds, Leeds, UK. [Schulze,M] Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany. [Key,T] Nuffield Department of Population Health, University of Oxford, Oxford, UK. [Khaw,KT] Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. [Tsilidis,KK, Ellingjord-Dale,M, Riboli,E] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [Tsilidis,KK] Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece., The coordination of the European Prospective Investigation into Cancer and Nutrition (EPIC) is supported financially by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (France), German Cancer Aid, German Cancer Research Center (German Cancer Research Center), Federal Ministry of Education and Research (Federal Ministry of Education and Research), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany), Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (Ministry of Health, Welfare and Sport), Netherlands Cancer Registry (Netherlands Cancer Registry), LK Research Funds, Dutch Prevention Funds, Dutch Zorg Onderzoek Nederland, World Cancer Research Fund, Statistics Netherlands (the Netherlands), Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), the Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO, Swedish Cancer Society, Swedish Research Council, and County Councils of Skåne and Västerbotten (Sweden), Cancer Research UK (14136 to EPIC-Norfolk, C570/A16491 and C8221/A19170 to EPIC-Oxford), and the Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK)., Tjønneland, Anne [0000-0003-4385-2097], Dahm, Christina C [0000-0003-0481-2893], Tumino, Rosario [0000-0003-2666-414X], and Borgquist, Signe [0000-0001-7938-8893]

Subjects
0301 basic medicine, Male, Breastfeeding, lcsh:Medicine, Breast carcinoma in situ, GUIDELINES, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Cohort Studies, 0302 clinical medicine, Breast cancer, Risk Factors, Medicine, Prospective Studies, Prospective cohort study, 11 Medical and Health Sciences, Medicine(all), Geographical Locations::Geographic Locations::Americas::North America::United States [Medical Subject Headings], Hazard ratio, Academies and Institutes, Cohort, General Medicine, Middle Aged, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Lifestyle Score, Europe, POSTMENOPAUSAL WOMEN, 030220 oncology & carcinogenesis, Female, CONCORDANCE, Life Sciences & Biomedicine, PROJECT, In situ breast cancer, Cohort study, Research Article, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Estudios de cohortes, RECREATIONAL PHYSICAL-ACTIVITY, Check Tags::Male [Medical Subject Headings], Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Data Collection::Nutrition Assessment [Medical Subject Headings], Breast Neoplasms, Estilo de vida, Càncer de mama, 03 medical and health sciences, Medicine, General & Internal, Medicina preventiva, DIETARY, General & Internal Medicine, Journal Article, Humans, VDP::Medisinske Fag: 700, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Carcinoma de mama in situ, Preventive medicine, 030109 nutrition & dietetics, Cancer prevention, Science & Technology, business.industry, Prevention, lcsh:R, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], medicine.disease, Lifestyle, United States, VDP::Medical disciplines: 700, Nutrition Assessment, Health Care::Health Care Economics and Organizations::Organizations::Academies and Institutes [Medical Subject Headings], Check Tags::Female [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], Cancer research, Life style, Geographical Locations::Geographic Locations::Europe [Medical Subject Headings], business
Abstract

Background Even though in situ breast cancer (BCIS) accounts for a large proportion of the breast cancers diagnosed, few studies have investigated potential risk factors for BCIS. Their results suggest that some established risk factors for invasive breast cancer have a similar impact on BCIS risk, but large population-based studies on lifestyle factors and BCIS risk are lacking. Thus, we investigated the association between lifestyle and BCIS risk within the European Prospective Investigation into Cancer and Nutrition cohort. Methods Lifestyle was operationalized by a score reflecting the adherence to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations. The recommendations utilized in these analyses were the ones pertinent to healthy body weight, physical activity, consumption of plant-based foods, energy-dense foods, red and processed meat, and sugary drinks and alcohol, as well as the recommendation on breastfeeding. Cox proportional hazards regression was used to assess the association between lifestyle score and BCIS risk. The results were presented as hazard ratios (HR) and corresponding 95% confidence intervals (CI). Results After an overall median follow-up time of 14.9 years, 1277 BCIS cases were diagnosed. Greater adherence to the WCRF/AICR cancer prevention recommendations was not associated with BCIS risk (HR = 0.98, 95% CI 0.93–1.03; per one unit of increase; multivariable model). An inverse association between the lifestyle score and BCIS risk was observed in study centers, where participants were recruited mainly via mammographic screening and attended additional screening throughout follow-up (HR = 0.85, 95% CI 0.73–0.99), but not in the remaining ones (HR = 0.99, 95% CI 0.94–1.05). Conclusions While we did not observe an overall association between lifestyle and BCIS risk, our results indicate that lifestyle is associated with BCIS risk among women recruited via screening programs and with regular screening participation. This suggests that a true inverse association between lifestyle habits and BCIS risk in the overall cohort may have been masked by a lack of information on screening attendance. The potential inverse association between lifestyle and BCIS risk in our analyses is consistent with the inverse associations between lifestyle scores and breast cancer risk reported from previous studies.

Published
2019
Full Text
View/download PDF

40. Effect of clinical signs, endocrinopathies, timing of surgery, hyperlipidemia, and hyperbilirubinemia on outcome in dogs with gallbladder mucocele

Author

Jaffey, J. A., Pavlick, M., Webster, C. R., Moore, G. E., McDaniel, K. A., Blois, S. L., Brand, E. M., Reich, C. F., Motschenbacher, L., Hostnik, E. T., Su, D., Lidbury, J. A., Raab, O., Carr, S. V., Mabry, K. E., Fox-Alvarez, W., Townsend, S., Palermo, S., Nakazono, Y., Ohno, K., VanEerde, E., Fieten, H., Hulsman, A. H., Cooley-Lock, K., Dunning, M., Kisielewicz, C., Zoia, A., Caldin, M., Conti-Patara, A., Ross, L., Mansfield, C., Lynn, O., Claus, M. A., Watson, P. J., Swallow, A., Yool, D. A., Gommeren, K., Knops, M., Ceplecha, V., de Rooster, H., Lobetti, R., Dossin, O., Jolivet, F., Papazoglou, L. G., Pappalardo, M. C.F., Manczur, F., Dudás-Györki, Z., O'Neill, E. J., Martinez, C., Gal, A., Owen, R. L., Gunn, E., Brown, K., Harder, L. K., Griebsch, C., Anfinsen, K. P., Gron, T. K., Marchetti, V., Heilmann, R. M., Pazzi, P., DeClue, A. E., dCSCA RMSC-1, dCSCA AVR, LS Interne geneeskunde, University of Missouri [Columbia] (Mizzou), University of Missouri System, Tufts University, Purdue University, University of Guelph, Michigan State University [East Lansing], Michigan State University System, University of Minnesota [Twin Cities] (UMN), University of Minnesota System, Ohio State University, Partenaires INRAE, University of Tennessee, Texas A&M University System, University of Prince Edward Island, Virginia Tech [Blacksburg], University of Florida [Gainesville] (UF), University of Pennsylvania, The University of Tokyo (UTokyo), Iowa State University (ISU), Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University [Utrecht], Department of Clinical Sciences, College of Veterinary Medicine, Cornell University [New York], University of Nottingham, UK (UON), San Marco Veterinary Clinic, Washington State University (WSU), University of Melbourne, Murdoch University, Department of Veterinary Medicine, University of Cambridge [UK] (CAM), University of Edinburgh, Université de Liège, University of Veterinary and Pharmaceutical Sciences [Brno] (VFU), Universiteit Gent = Ghent University [Belgium] (UGENT), Bryanston Veterinary Hospital, Institut de Recherche en Santé Digestive (IRSD ), Institut National de la Recherche Agronomique (INRA)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Aristotle University of Thessaloniki, Department of Support, Production and Animal Health, School of Veterinary Medicine, University of Veterinary Medicine, University of Dublin, Massey University, University of Glasgow, University of Veterinary Medicine Hannover, Department of Animal Nutrition, University of Sydney, Department of Companion Animal Clinical Sciences, Norwegian School of Veterinary Science, University of Pisa, Leipzig University, University of Pretoria [South Africa], Pride Veterinary Centre, dCSCA RMSC-1, dCSCA AVR, LS Interne geneeskunde, Watson, Penelope [0000-0002-7241-9412], and Apollo - University of Cambridge Repository

Subjects
Canine Cushing's, Adrenocortical Hyperfunction, [SDV.BIO]Life Sciences [q-bio]/Biotechnology, Survival, Mucocele, Gallbladder mucocoele, Gastroenterology, 0403 veterinary science, 0302 clinical medicine, gallbladder mucocele, dog, endocrinopathies, Dog Diseases, Subclinical infection, Hyperbilirubinemia, Mortality rate, 04 agricultural and veterinary sciences, Jaundice, 3. Good health, Treatment Outcome, dog, 030211 gastroenterology & hepatology, medicine.symptom, Prognostic variable, medicine.medical_specialty, 040301 veterinary sciences, Gallbladder disease, Hyperlipidemias, Gallbladder Diseases, Canine Cushing’s, 03 medical and health sciences, Dogs, Hypothyroidism, Internal medicine, Diabetes mellitus, medicine, Animals, Genetic Predisposition to Disease, Cholecystectomy, Retrospective Studies, [SDV.BA.MVSA]Life Sciences [q-bio]/Animal biology/Veterinary medicine and animal Health, General Veterinary, business.industry, Retrospective cohort study, Bilirubin, medicine.disease, veterinary(all), endocrinopathies, Animal Science and Zoology, gallbladder mucocele, business, Biomarkers
Abstract

International audience; Gallbladder mucocele (GBM) is a common extra-hepatic biliary syndrome in dogs with death rates ranging from 7 to 45%. Therefore, the aim of this study was to identify the association of survival with variables that could be utilized to improve clinical decisions. A total of 1194 dogs with a gross and histopathological diagnosis of GBM were included from 41 veterinary referral hospitals in this retrospective study. Dogs with GBM that demonstrated abnormal clinical signs had significantly greater odds of death than subclinical dogs in a univariable analysis (OR, 4.2; 95% CI, 2.14–8.23; P < 0.001). The multivariable model indicated that categorical variables including owner recognition of jaundice (OR, 2.12; 95% CI, 1.19–3.77; P = 0.011), concurrent hyperadrenocorticism (OR 1.94; 95% CI, 1.08–3.47; P = 0.026), and Pomeranian breed (OR, 2.46; 95% CI 1.10–5.50; P = 0.029) were associated with increased odds of death, and vomiting was associated with decreased odds of death (OR, 0.48; 95% CI, 0.30–0.72; P = 0.001). Continuous variables in the multivariable model, total serum/plasma bilirubin concentration (OR, 1.03; 95% CI, 1.01– 1.04; P < 0.001) and age (OR, 1.17; 95% CI, 1.08–1.26; P < 0.001), were associated with increased odds of death. The clinical utility of total serum/plasma bilirubin concentration as a biomarker to predict death was poor with a sensitivity of 0.61 (95% CI, 0.54–0.69) and a specificity of 0.63 (95% CI, 0.59–0.66). This study identified several prognostic variables in dogs with GBM including total serum/plasma bilirubin concentration, age, clinical signs, concurrent hyperadrenocorticism, and the Pomeranian breed. The presence of hypothyroidism or diabetes mellitus did not impact outcome in this study.

Published
2019
Full Text
View/download PDF

41. Effectiveness of a telephone-based intervention for smoking cessation in patients with severe mental disorders : Study protocol for a randomized controlled trial

Author

Ballbè, M., Martínez, C., Feliu, A., Torres, N., Nieva, Gemma, Pinet, C., Raich, A., Mondon, S., Barrio, P., Hernández-Ribas, R., Vicens, J., Costa, Silvia, Vilaplana, J., Alaustre, L., Vilalta, E., Blanch, R., Subirà, S., Bruguera, Eugeni, Suelves, J. M., Guydish, J., Fernández, E., Universitat Autònoma de Barcelona, Institut Català de la Salut, [Ballbè M] Tobacco Control Unit, Cancer Control and Prevention Program, Institut Català d'Oncologia-ICO, L'Hospitalet de Llobregat, Barcelona, Spain. Cancer Control and Prevention Group, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. Addictions Unit, Institute of Neurosciences, Hospital Clínic de Barcelona, Barcelona, Spain. [Martínez C] Tobacco Control Unit, Cancer Control and Prevention Program, Institut Català d'Oncologia-ICO, L'Hospitalet de Llobregat, Barcelona, Spain. Cancer Control and Prevention Group, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. Medicine and Health Sciences School, Universitat Internacional de Catalunya, Sant Cugat del Valles, Barcelona, Spain. Department of Clinical Sciences, School of Medicine, Universitat de Barcelona, L'Hospitalet del Llobregat, Barcelona, Spain. [Feliu A] Tobacco Control Unit, Cancer Control and Prevention Program, Institut Català d'Oncologia-ICO, L'Hospitalet de Llobregat, Barcelona, Spain. Cancer Control and Prevention Group, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. Department of Clinical Sciences, School of Medicine, Universitat de Barcelona, L'Hospitalet del Llobregat, Barcelona, Spain. [Torres N] 061 CatSalut Respon, Sistema d'Emergències Mèdiques, L'Hospitalet de Llobregat, Barcelona, Spain. [Nieva G] Servei de Psiquiatria, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d’Hebron Institut de Recerca, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. [Pinet C] Addictive Behaviors Unit, Psychiatry Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Bruguera E] Servei de Psiquiatria, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d’Hebron Institut de Recerca, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., Hospital Universitari Vall d'Hebron, Universitat de Barcelona, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, Other subheadings::/methods [Other subheadings], Personas::Personas con Discapacidad::Enfermos Mentales [DENOMINACIONES DE GRUPOS], Instalaciones para Atención de Salud, Recursos Humanos y Servicios::Servicios de Salud::Servicios Médicos de Urgencia::Líneas Directas [ATENCIÓN DE SALUD], medicine.medical_treatment, Smoking Prevention, Mental disorders, Smoking cessation, Cardiovascular, law.invention, Pathological psychology, Study Protocol, 0302 clinical medicine, Otros calificadores::/métodos [Otros calificadores], Medicine, Multicenter Studies as Topic, Pharmacology (medical), Características de los Estudios::Estudio Clínico::Ensayo Clínico [CARACTERÍSTICAS DE PUBLICACIONES], media_common, Cancer, education.field_of_study, Smoking Cessation Agents, Tobacco Use Disorder, Tabaquisme - Tractament, Clinical trial, Estudi de casos, Health Care Facilities, Manpower, and Services::Health Services::Emergency Medical Services::Hotlines [HEALTH CARE], Number needed to treat, Respiratory, lcsh:Medicine (General), medicine.medical_specialty, media_common.quotation_subject, Clinical Trials and Supportive Activities, Clinical Sciences, 03 medical and health sciences, características del estudio::estudio clínico::ensayo clínico [CARACTERÍSTICAS DE PUBLICACIONES], Clinical Research, Study Characteristics::Clinical Study::Clinical Trial [PUBLICATION CHARACTERISTICS], Humans, education, Persons::Disabled Persons::Mentally Ill Persons [NAMED GROUPS], Aged, Tobacco Smoke and Health, Prevention, Odds ratio, Abstinence, Prevention of disease and conditions, Psicopatologia, personas::personas con discapacidad::personas con enfermedad mental [DENOMINACIONES DE GRUPOS], 3.1 Primary prevention interventions to modify behaviours or promote wellbeing, Telèfon, 030217 neurology & neurosurgery, Comparative Effectiveness Research, and promotion of well-being, Time Factors, Medicine (miscellaneous), Cardiorespiratory Medicine and Haematology, Randomized controlled trial, law, Single-Blind Method, 030212 general & internal medicine, lcsh:R5-920, Cardiovascular Medicine And Haematology, Conducta y Mecanismos de Conducta::Conducta::Conductas Relacionadas con la Salud::Cese del Hábito de Fumar [PSIQUIATRÍA Y PSICOLOGÍA], Smoking, Substance Abuse, Middle Aged, Combined Modality Therapy, Stroke, Quitline, Treatment Outcome, Mental Health, Behavior and Behavior Mechanisms::Behavior::Health Behavior::Smoking Cessation [PSYCHIATRY AND PSYCHOLOGY], Female, Protocols clínics, Adult, Quitlines, Adolescent, Population, Assessorament psicològic per telèfon, Young Adult, Patient Education as Topic, General & Internal Medicine, Pragmatic Clinical Trials as Topic, Tobacco, Tractament del tabaquisme, business.industry, instalaciones, servicios y personal de asistencia sanitaria::servicios de salud::servicios médicos de urgencia::líneas directas [ATENCIÓN DE SALUD], Mental health, Brain Disorders, Medical protocols, Telephone, Good Health and Well Being, Cardiovascular System & Hematology, Spain, Physical therapy, Case studies, business, Malalties mentals, conducta y mecanismos de la conducta::conducta::conducta sanitaria::cese del hábito de fumar [PSIQUIATRÍA Y PSICOLOGÍA], Assaigs clínics
Abstract

Background Up to 75% of inpatients with mental disorders smoke, and their life expectancy is decreased by up to 25 years compared to the general population. Hospitalized patients without monitoring after discharge quickly return to prehospitalization levels of tobacco use. The aim of the 061 QuitMental study is to assess the effectiveness of a multicomponent and motivational telephone-based intervention to stop smoking through a quitline addressed to smokers discharged from mental health hospital wards. Methods A pragmatic randomized controlled trial, single blinded, will include 2:1 allocation to the intervention group (IG) and the control group (CG). The IG will receive telephone assistance to quit smoking (including psychological and psychoeducational support, and pharmacological treatment advice if required) proactively for 12 months, and the CG will receive only brief advice after discharge. The sample size, calculated with an expected difference of 15 points on smoking abstinence between groups (IG, 20% and CG, 5%), α = 0.05, β = 0.10, and 20% loss, will be 334 participants (IG) and 176 participants (CG). Participants are adult smokers discharged from psychiatric units of five acute hospitals. Measurements include dependent variables (self-reported 7-day point prevalence smoking abstinence (carbon monoxide verified), duration of abstinence, number of quit attempts, motivation, and self-efficacy to quit) and independent variables (age, sex, and psychiatric diagnoses). In data analysis, IG and CG data will be compared at 48 h and 1, 6, and 12 months post discharge. Multivariate logistic regression (odds ratio; 95% confidence interval) of dependent variables adjusted for potential confounding variables will be performed. The number needed to treat to achieve one abstinence outcome will be calculated. We will compare the abstinence rate of enrolled patients between groups. Discussion This trial evaluates an innovative format of a quitline for smokers with severe mental disorders regardless of their motivation to quit. If effective, the pragmatic nature of the study will permit transfer to routine clinical practice in the National Health System. Trial registration ClinicalTrials.gov, NCT03230955. Registered on 24 July 2017. Electronic supplementary material The online version of this article (10.1186/s13063-018-3106-5) contains supplementary material, which is available to authorized users.

Published
2019
Full Text
View/download PDF

43. Titanium granules pre‑treated with hydrogen peroxide inhibit growth of bacteria associated with post‑operative infections in spine surgery

Author

Stéphane Corvec, Acke Ohlin, Julia R. Davies, Kristian Riesbeck, Pentti Tengvall, Gunnel Svensäter, Emma Mattsson, Matthias Mörgelin, Department of Clinical Sciences [Malmö, Sweden] ( Orthopaedics ), Lund University [Lund, Sweden], Department of Translational Medicine [Malmö, Sweden] ( Clinical Microbiology ), Department of Clinical Sciences [Lund, Sweden] ( Section of Infectious Medicine ), Department of Oral Biology [Malmö, Sweden] ( Faculty of Odontology ), Malmø University, Clinical and translational research in skin cancer ( CRCINA - Département INCIT - Equipe 2 ), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers ( CRCINA ), Université d'Angers ( UA ) -Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche en Santé de l'Université de Nantes ( IRS-UN ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ) -Université d'Angers ( UA ) -Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche en Santé de l'Université de Nantes ( IRS-UN ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ), Unité de bactériologie et d'hygiène [CHU Nantes] ( Institut de biologie ), Centre hospitalier universitaire de Nantes ( CHU Nantes ), Sahlgrenska Academy at University of Gothenburg [Göteborg], This work was supported by grants from the Anna and Edwin Berger Foundation, Medical Research Council (Grant Number K2015-57X-03163-43-4, www.vr.se) and Skåne County Council’s Research and Development Foundation., Department of Clinical Sciences [Malmö, Sweden] (Orthopaedics), Department of Translational Medicine [Malmö, Sweden] (Clinical Microbiology), Department of Clinical Sciences [Lund, Sweden] (Section of Infectious Medicine), Department of Oral Biology [Malmö, Sweden] (Faculty of Odontology), Clinical and Translational Research in Skin Cancer (CRCINA-ÉQUIPE 2), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Unité de bactériologie et d'hygiène [CHU Nantes] (Institut de biologie), Centre hospitalier universitaire de Nantes (CHU Nantes), Bernardo, Elizabeth, Lund University [Lund], Malmö Högskola = Malmö University, and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)

Subjects
Medicin och hälsovetenskap, Staphylococcus aureus, Prosthesis-Related Infections, Surface Properties, Klebsiella pneumoniae, [SDV.CAN]Life Sciences [q-bio]/Cancer, Microbial Sensitivity Tests, Growth, medicine.disease_cause, Medical and Health Sciences, Microbiology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Postoperative Complications, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, medicine, Humans, Orthopedics and Sports Medicine, 030212 general & internal medicine, Parvimonas micra, Titanium, biology, Bacteria, business.industry, Pseudomonas aeruginosa, Prostheses and Implants, Antibiotic Prophylaxis, Staphylococcal Infections, biology.organism_classification, Antimicrobial, Hydrogen peroxide, Proteus mirabilis, Spine, Anti-Bacterial Agents, 3. Good health, Surgery, Anaerobic bacteria, business, 030217 neurology & neurosurgery, Titanium peroxy
Abstract

PURPOSE: Post-operative infections are relatively common after posterior spine surgery, and there are several observations reflecting different infection complications related to various metals implanted. Here, we selected an array of different bacterial species that are often found in infections associated with orthopaedic implants and tested for inhibition by hydrogen peroxide-treated titanium (Ti-peroxy). METHODS: To study the possibility of using Ti-peroxy as an antimicrobial prophylaxis, we developed a protocol for standardized susceptibility testing of bacteria. RESULTS: Importantly, we found that the resulting Ti-peroxy was highly antimicrobial against all aerobic species tested, among others, Staphylococcus aureus and Pseudomonas aeruginosa. Proteus mirabilis was slightly more resistant than, for example, Klebsiella pneumoniae and enterococci. In contrast, anaerobic bacteria Cutibacterium acnes and Parvimonas micra were equally susceptible compared to staphylococci. CONCLUSIONS: Our findings suggest that the Ti-peroxy is a promising perioperative antimicrobial strategy that may be highly effective for prevention of post-operative infections. We therefore suggest application of hydrogen peroxide to implants prior to implantation. These slides can be retrieved under Electronic supplementary material.

Published
2018
Full Text
View/download PDF

46. Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population

Author

Rayjean J. Hung, Vladimir Janout, Natasha B. Leighl, Geoffrey Liu, David C. Christiani, Kim Overvad, Beata Swiatkowska, Eric J. Duell, David C. Muller, Aage Haugen, Angeline S. Andrew, Jonas Manjer, Mattias Johansson, David Zaridze, Mikael Johansson, Simona Ognjanovic, Demetrios Albanes, H-Erich Wichmann, Jolanta Lissowska, Kjell Grankvist, Angela Cecilia Pesatori, David C. Qian, Younghun Han, Richard S. Houlston, Matthew B. Schabath, James D. McKay, Pier Alberto Bertazzi, Matt J. Barnett, Lambertus A. Kiemeney, Michael W. Marcus, Penella J. Woll, Gad Rennert, Tadeusz M Orlowski, Gary E. Goodman, Stephen Lam, Lesley M. Butler, Loic Le Marchand, Ciprian Bolca, Antonia Trichopoulou, Paul Brennan, Rosario Tumino, María Soler Artigas, Melinda C. Aldrich, Stig E. Bojesen, Ghislaine Scelo, Vidar Skaug, Xifeng Wu, Judith Manz, William S. Bush, Olle Melander, Olga Y. Gorlova, Susanne M. Arnold, Jakob S Johansen, Hans Brunnström, Xiangjun Xiao, Ivana Holcatova, John K. Field, Angela Risch, Philip Lazarus, Eric B. Haura, Anush Mukeria, Yafang Li, Angela Cox, Frances A. Shepherd, Neil E. Caporaso, Heike Bickeböller, Albert Rosenberger, Fiona Taylor, Shanbeh Zienolddiny, Milica Kontic, M. Dawn Teare, Per Bakke, Adonina Tardón, Chu Chen, Thomas Muley, Christopher I. Amos, Nofer Institute of Occupational Medicine, Biomedical Data Science Department, Dartmouth College, Hanover, NH, USA, Department of Medicine, The Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada, Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen University, Herlev, Denmark, Public Health Sciences Division, Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, Public Health Sciences Division, Cancer Prevention Program, Swedish Medical Center, Seattle, WA, USA, Department of Oncology, University of Sheffield, Sheffield UK, Institute of Epidemiology, Helmholtz Centre Munich, Neuherberg, Germany, Biobank and Tumor Documentation, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany, Department of Genetic Epidemiology, Medical School, Georg-August University of Göttingen, Göttingen, Germany, Markey Cancer Center, University of Kentucky, Lexington, KY, USA, Department of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA, Thoracic Surgery Division, 'Marius Nasta' National Institute of Pneumology, București, Romania, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic, Internal Medicine, School of Medicine, Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia, Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Cancer Center, Institute of Oncology, Warsaw, Pol, Department of Epidemiology and Prevention, Russian N.N. Blokhin Cancer Research Centre, Moscow, Russia, International Organization for Cancer Prevention and Research, Belgrade, Serbia, Department of Thoracic Surgery, National Institute of Tuberculosis and Lung Diseases, Warsaw, Pol, International Agency for Research on Cancer (IARC), Genetic Epidemiology Group, Lyon, France, Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Łódź, Pol, Department of Clinical Science, University of Bergen, Bergen, Norway, Department of Toxicology, National Institute of Occupational Health, Oslo, Norway, Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO-IDIBELL), Hospitalet de Llobregat, Barcelona, Spain, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA, The Institute of Cancer Research, London, UK, Department of Health Sciences, Genetic Epidemiology Group, University of Leicester, Leicester, UK, Department of Medical Biosciences, Umeå University, Umeå, Sweden, Department of Radiation Sciences, Umeå University, Umeå, Sweden, Medical Oncology Toronto, Princess Margaret Hospital, Toronto, ON, Canada, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK, Department of Clinical Sciences, Lund University, Lund, Sweden, Department of Internal Medicine, Skåne University Hospital, Malmö, Sweden, Department of Epidemiology and Biostatistics, Imperial College London, St Mary’s Campus, London, UK, Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus C, Denmark, Department of Hygiene and Epidemiology, Medical School, University of Athens, Athens, Greece, Molecular and Nutritional Epidemiology Unit, CSPO (Cancer Research and Prevention Centre), Scientific Institute of Tuscany, Florence, Italy, Princess Margaret Cancer Centre, Toronto, ON M5G, Canada, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark, Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA, Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA, Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Bethesda, MD, USA, Department of Genetic Epidemiology, University Medical Center, Georg-August University Göttingen, Göttingen, Germany, Department of Thoracic Surgery, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA, Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA, Medicina, IUOPA-Universidad de Oviedo, Oviedo, Spain, Technion Faculty of Medicine, Clalit National Cancer Control Center, Carmel Medical Center, Haifa, Israel, Genetic Epidemiology, School of Health and Related Research, University of Sheffield, Sheffield, UK, Institute of Translational Medicine, University of Liverpool, Liverpool, UK, Department for Health Evidence, Radboud University Medical Center, Nijmegen EZ, Netherlands, Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, WA, USA, Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada, Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, Department of Epidemiology, Norris Cotton Cancer Center, Dartmouth College, Hanover, NH, USA, Department of Preventive Medicine, IRCCS Foundation Cà Granda Ospedale, Maggiore Policlinico, University of Milan, Milan, Italy, Department of Clinical Sciences and Community Health–DISCCO, University of Milan, Milan, Italy, Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA, International Agency for Research on Cancer, World Health Organization, Lyon, France, and Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada

Subjects
0301 basic medicine, Cancer Research, Carcinogenesis, Population, Genome-wide association study, Single-nucleotide polymorphism, Bioinformatics, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Hàbit de fumar, 0302 clinical medicine, Missing heritability problem, Genotype, Journal Article, medicine, Carcinogènesi, Oncology & Carcinogenesis, Lung cancer, education, education.field_of_study, business.industry, Smoking, Case-control study, General Medicine, Odds ratio, medicine.disease, 3. Good health, 030104 developmental biology, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], 030220 oncology & carcinogenesis, Càncer de pulmó, business, 1112 Oncology And Carcinogenesis
Abstract

Non-small cell lung cancer is the most common type of lung cancer. Both environmental and genetic risk factors contribute to lung carcinogenesis. We conducted a genome-wide interaction analysis between single nucleotide polymorphisms (SNPs) and smoking status (never-versus ever-smokers) in a European-descent population. We adopted a two-step analysis strategy in the discovery stage: we first conducted a case-only interaction analysis to assess the relationship between SNPs and smoking behavior using 13 336 non-small cell lung cancer cases. Candidate SNPs with P-value

Published
2017
Full Text
View/download PDF

47. Impact of fat mass and distribution on lipid turnover in human adipose tissue

Author

Lena Appelsved, Henrik Druid, Mikael Rydén, Peter Arner, Keng-Yeh Fu, Anders Thorell, Göran Possnert, Mehran Salehpour, Kanar Alkass, Kirsty L. Spalding, Samuel Bernard, Erik Näslund, Department of Cell and Molecular Biology [Stockholm], Karolinska Institutet [Stockholm], Multi-scale modelling of cell dynamics : application to hematopoiesis (DRACULA), Institut Camille Jordan [Villeurbanne] (ICJ), École Centrale de Lyon (ECL), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-École Centrale de Lyon (ECL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Inria Grenoble - Rhône-Alpes, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de génétique et de physiologie moléculaire et cellulaire (CGPhiMC), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Modélisation mathématique, calcul scientifique (MMCS), Division of Surgery, Department of Clinical Sciences, Karolinska Institutet [Stockholm]-Danderyd Hospital, Department of Physics and Astronomy [Uppsala], Uppsala University, Nanjing Agricultural University, Jiangsu Academy of Agricultural Sciences, Department of Forensic Medicine [Stockholm], Department of Clinical Sciences, Danderyd Hospital, Department of medicine [Stockholm], Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm], Centre de génétique et de physiologie moléculaire et cellulaire (CGPhiMC), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Inria Grenoble - Rhône-Alpes, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut Camille Jordan (ICJ), Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS)-École Centrale de Lyon (ECL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), Institut Camille Jordan (ICJ), Karolinska Institutet [Stockholm]-Danderyds sjukhus = Danderyd University Hospital, Nanjing Agricultural University (NAU), and Danderyds sjukhus = Danderyd University Hospital

Subjects
0301 basic medicine, Adult, medicine.medical_specialty, Science, [MATH.MATH-DS]Mathematics [math]/Dynamical Systems [math.DS], General Physics and Astronomy, Adipose tissue, Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy), 030209 endocrinology & metabolism, White adipose tissue, Overweight, Biology, General Biochemistry, Genetics and Molecular Biology, Article, Body Mass Index, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Waist–hip ratio, Internal medicine, medicine, Adipocytes, Humans, Carbon Radioisotopes, Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci), Triglycerides, Adiposity, Cell Size, Multidisciplinary, Triglyceride, Anthropometry, Waist-Hip Ratio, Radiometric Dating, Lipid metabolism, General Chemistry, medicine.disease, Lipid Metabolism, Obesity, 030104 developmental biology, Endocrinology, Phenotype, chemistry, Adipose Tissue, medicine.symptom, Waist Circumference, Body mass index
Abstract

Differences in white adipose tissue (WAT) lipid turnover between the visceral (vWAT) and subcutaneous (sWAT) depots may cause metabolic complications in obesity. Here we compare triglyceride age and, thereby, triglyceride turnover in vWAT and sWAT biopsies from 346 individuals and find that subcutaneous triglyceride age and storage capacity are increased in overweight or obese individuals. Visceral triglyceride age is only increased in excessively obese individuals and associated with a lower lipid removal capacity. Thus, although triglyceride storage capacity in sWAT is higher than in vWAT, the former plateaus at substantially lower levels of excess WAT mass than vWAT. In individuals with central or visceral obesity, lipid turnover is selectively increased in vWAT. Obese individuals classified as ‘metabolically unhealthy' (according to ATPIII criteria) who have small subcutaneous adipocytes exhibit reduced triglyceride turnover. We conclude that excess WAT results in depot-specific differences in lipid turnover and increased turnover in vWAT and/or decreased turnover in sWAT may result in metabolic complications of overweight or obesity., Lipid turnover in tissues can be calculated from ratios of different carbon isotopes. Here the authors use this approach to study lipid turnover in two distinct adipose tissue depots and find that, in obese individuals, visceral fat is more lipolytic than subcutaneous fat.

Published
2017
Full Text
View/download PDF

48. A Nested Case-Control Study of Metabolically Defined Body Size Phenotypes and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)

Author

Murphy, N, Cross, A, Abubakar, M, Jenab, M, Aleksandrova, K, Boutron-Ruault, M, Dossus, L, Racine, A, Kühn, T, Katzke, V, Tjønneland, A, Petersen, K, Overvad, K, Quirós, JR, Jakszyn, P, Molina-Montes, E, Dorronsoro, M, Huerta, J, Barricarte, A, Khaw, K, Wareham, N, Travis, R, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Masala, G, Krogh, V, Tumino, R, Vineis, P, Panico, S, Bueno-de-Mesquita, H, Siersema, P, Peeters, P, Ohlsson, B, Ericson, U, Palmqvist, R, Nyström, H, Weiderpass, E, Skeie, G, Freisling, H, Kong, S, Tsilidis, K, Muller, D, Riboli, E, Gunter, M, [Murphy,N, Cross,AJ, Vineis,P, Bueno-de-Mesquita,HB, Tsilidis,K, Riboli,E, Gunter,MJ] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.[Abubakar,M] Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom. [Jenab,M, Freisling,M, Kong,SY, Mulle,DC, Gunter,MJ] International Agency for Research on Cancer, World Health Organization, Lyon, France. [Aleksandrova,K] Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Potsdam, Germany. [Boutron-Ruault,M, Dossus,L, Racine,A] Inserm, Nutrition, Hormones and Women’s Health, Centre for Research in Epidemiology and Population Health (CESP), U1018, Villejuif, France. Université Paris Sud, UMRS 1018, Villejuif, France. Institut Gustave Roussy, Villejuif, France. [Kühn,T, Katzke,VA] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Tjønneland,A, Petersen,KEN] Danish Cancer Society Research Center, Copenhagen, Denmark. [Overvad,K] Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark. [Quirós,JR] Public Health Directorate, Asturias, Spain. [Jakszyn,P] Unit of Nutrition, Environment and Cancer, Catalan Institute of Oncology, Barcelona, Spain. [Molina-Montes,E] Andalusian School of Public Health, Granada, Spain. [Molina-Montes,E, Huerta,J, Barricarte,A] Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), Madrid, Spain. [Dorronsoro,M] Public Health Direction and Biodonostia–CIBERESP, Basque Regional Health Department, Vitoria, Spain. [Huerta,J] Department of Epidemiology, Murcia Regional Health Council, Murcia, Spain. [Barricarte,A] Navarre Public Health Institute, Pamplona, Spain. [Khaw,K] University of Cambridge, Cambridge, United Kingdom. [Wareham,N] MRC Epidemiology Unit, Cambridge, United Kingdom. [Travis,RC] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. [Trichopoulou,A, Trichopoulos,D] Hellenic Health Foundation, Athens, Greece. [Trichopoulou,A, Lagiou,P] Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece. [Trichopoulou,A, Lagiou,P, Trichopoulos,D] Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece. [Lagiou,P, Trichopoulos,D] Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America. [Masala,G] Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy. [Krogh,V] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Tumino,R] Cancer Registry and Histopathology Unit, Civic–M.P.Arezzo Hospital, Azienda Sanitaria Provinciale di Ragusa, Italy. [Vineis,P] HuGeF Foundation, Torino, Italy. [Panico,S] Dipartimento di Medicina Clinica e Sperimentale, Federico II University, Naples, Italy. [Bueno-de- Mesquita,HB] Department of Determinants of Chronic Diseases, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia [Bueno-de-Mesquita,HB, Siersema,PD] Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands. [Peeters,PH] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. [Ohlsson,B] Division of Internal Medicine, Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö, Sweden. [Ericson,U] Diabetes and Cardiovascular Disease–Genetic Epidemiology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö, Lund University, Sweden. [Palmqvist,R, Nyström,H] Medical Bioscience, Umeå University, Umeå, Sweden. [Weiderpass,E, Skeie,G] Department of Community Medicine, Faculty of Health Sciences, University of Tromsø–The Arctic University of Norway, Tromsø, Norway. [Weiderpass,E] Cancer Registry of Norway, Oslo, Norway. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Department of Genetic Epidemiology, Folkhälsan Research Center, Helsinki, Finland. [Tsilidis,K] Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece., Funding: The coordination of EPIC is financially supported by the European Commission (DGSANCO), and the International Agency for Research on Cancer., University Medical Center Utrecht, Imperial College Trust, Murphy, Neil, Cross, Amanda J, Abubakar, Mustapha, Jenab, Mazda, Aleksandrova, Krasimira, Boutron Ruault, Marie Christine, Dossus, Laure, Racine, Antoine, Kühn, Tilman, Katzke, Verena A, Tjønneland, Anne, Petersen, Kristina E. N, Overvad, Kim, Quirós, J. Ramón, Jakszyn, Paula, Molina Montes, Esther, Dorronsoro, Miren, Huerta, José María, Barricarte, Aurelio, Khaw, Kay Tee, Wareham, Nick, Travis, Ruth C, Trichopoulou, Antonia, Lagiou, Pagona, Trichopoulos, Dimitrio, Masala, Giovanna, Krogh, Vittorio, Tumino, Rosario, Vineis, Paolo, Panico, Salvatore, Bueno de Mesquita, H. Ba, Siersema, Peter D, Peeters, Petra H, Ohlsson, Bodil, Ericson, Ulrika, Palmqvist, Richard, Nyström, Hanna, Weiderpass, Elisabete, Skeie, Guri, Freisling, Heinz, Kong, So Yeon, Tsilidis, Kosta, Muller, David C, Riboli, Elio, Gunter, Marc J., Khaw, Kay-Tee [0000-0002-8802-2903], Wareham, Nicholas [0000-0003-1422-2993], and Apollo - University of Cambridge Repository

Subjects
Male, Phenomena and Processes::Genetic Phenomena::Phenotype [Medical Subject Headings], Cell- och molekylärbiologi, Obesidad, Biochemistry, Body Mass Index, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Endocrinology, Odds Ratio, Insulin, Prospective Studies, Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Body Weight::Overweight [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings], Adiposity, VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801, C-Peptide, Incidence, 11 Medical And Health Sciences, Oncology, Medicine, Waist Circumference, Fenotipo, Human, Logistic Model, Colon, Risk Assessment, Hyperinsulinism, Gastrointestinal Tumors, Neoplasias Colorrectales, Humans, Comparative Study, Diseases::Cardiovascular Diseases [Medical Subject Headings], Protective Factor, Cancer och onkologi, Chi-Square Distribution, Biology and Life Sciences, nutritional and metabolic diseases, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings], Biomarker, Hormones, Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings], Prospective Studie, Logistic Models, Case-Control Studies, Cancer and Oncology, Digestive System, Biomarkers, Cell and Molecular Biology, Metabolic Processes, Physiology, Health Status, Colorectal Neoplasm, Health Statu, Risk Factors, Medicine and Health Sciences, Body Size, Multivariate Analysi, Tamaño Corporal, Enfermedades Cardiovasculares, Medicine(all), Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings], Research Support, Non-U.S. Gov't, Estudios de Casos y Controles, Estudios Prospectivos, Middle Aged, Multicenter Study, Europe, Phenotype, Physiological Parameters, Female, Anatomy, Colorectal Neoplasms, Case-Control Studie, Research Article, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Size [Medical Subject Headings], Rectal Cancer, Research Support, N.I.H., Extramural, General & Internal Medicine, Journal Article, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperinsulinism [Medical Subject Headings], Obesity, Colorectal Cancer, Diabetic Endocrinology, Obesity, Metabolically Benign, Hiperinsulinismo, Risk Factor, Body Weight, Cancers and Neoplasms, Protective Factors, Gastrointestinal Tract, Metabolism, Sobrepeso, Multivariate Analysis, VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801, Prevalencia
Abstract

Background Obesity is positively associated with colorectal cancer. Recently, body size subtypes categorised by the prevalence of hyperinsulinaemia have been defined, and metabolically healthy overweight/obese individuals (without hyperinsulinaemia) have been suggested to be at lower risk of cardiovascular disease than their metabolically unhealthy (hyperinsulinaemic) overweight/obese counterparts. Whether similarly variable relationships exist for metabolically defined body size phenotypes and colorectal cancer risk is unknown. Methods and Findings The association of metabolically defined body size phenotypes with colorectal cancer was investigated in a case–control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Metabolic health/body size phenotypes were defined according to hyperinsulinaemia status using serum concentrations of C-peptide, a marker of insulin secretion. A total of 737 incident colorectal cancer cases and 737 matched controls were divided into tertiles based on the distribution of C-peptide concentration amongst the control population, and participants were classified as metabolically healthy if below the first tertile of C-peptide and metabolically unhealthy if above the first tertile. These metabolic health definitions were then combined with body mass index (BMI) measurements to create four metabolic health/body size phenotype categories: (1) metabolically healthy/normal weight (BMI < 25 kg/m2), (2) metabolically healthy/overweight (BMI ≥ 25 kg/m2), (3) metabolically unhealthy/normal weight (BMI < 25 kg/m2), and (4) metabolically unhealthy/overweight (BMI ≥ 25 kg/m2). Additionally, in separate models, waist circumference measurements (using the International Diabetes Federation cut-points [≥80 cm for women and ≥94 cm for men]) were used (instead of BMI) to create the four metabolic health/body size phenotype categories. Statistical tests used in the analysis were all two-sided, and a p-value of, Gunter and colleagues analyse a large European dataset to determine how body size and metabolic profile associates with the risk of developing colorectal cancer., Editors' Summary Background Colorectal cancer is the third most common cancer worldwide and is a leading cause of cancer-related death, killing around 700,000 people every year. It develops when cells in the colon (the final part of the digestive system, which is also known as the large intestine or large bowel) or the rectum (the lower end of the colon) acquire genetic changes that allow them to divide uncontrollably to form a tumor and to move around the body (metastasize). Symptoms of colorectal cancer include blood in the stool, a change in bowel habits, and unexplained weight loss. Treatments for colorectal cancer include surgery, chemotherapy, and radiation. As with other types of cancer, these treatments are more likely to be successful if started when the tumor is very small. Consequently, many countries run screening programs that use colonoscopy, the fecal occult blood test, and other tests to detect the earliest signs of colorectal cancer in apparently healthy people. Why Was This Study Done? Being obese—having too much body fat—is associated with an increased colorectal cancer risk (other risk factors include age, having a family history of colorectal cancer, and eating a high-fat, low-fiber diet). Obesity is also associated with several other chronic diseases, and recent evidence suggests that some obese individuals have a higher risk of developing these diseases than others. For example, overweight/obese individuals who have hyperinsulinemia (abnormally high blood levels of insulin; “metabolically unhealthy”) seem to have a higher risk of cardiovascular disease than their non-hyperinsulinemic (“metabolically healthy”) overweight counterparts. If certain combinations of metabolic health status and body size (“metabolically defined body size phenotypes”) are also associated with colorectal cancer, measurement of insulin levels in conjunction with body fat (adiposity) measurements such as body mass index (BMI; an indicator of body fat calculated by dividing a person’s weight in kilograms by their height in meters squared) might improve colorectal cancer risk assessment. In this nested case–control study, the researchers assess the associations between metabolically defined body size phenotypes and colorectal cancer risk. A nested case–control study identifies everyone in a group (here, participants in the European Prospective Investigation into Cancer and Nutrition [EPIC] study) who has a specific condition, identifies matched individuals in the same group without the condition, and asks whether these controls and the cases differ in terms of a specific characteristic or outcome. What Did the Researchers Do and Find? The researchers matched 737 participants in the EPIC study who developed colorectal cancer after study enrollment with 737 controls and used serum concentrations of C-peptide, a marker of insulin secretion, and BMI measurements to classify each individual as metabolically healthy/normal weight, metabolically healthy/overweight, metabolically unhealthy/normal weight, or metabolically unhealthy/overweight. Specifically, the researchers categorized people as metabolically unhealthy if they had a C-peptide level above an arbitrarily chosen cut-off value based on the distribution of C-peptide levels in the control participants and as overweight if they had a BMI of ≥25 kg/m2 (the standard definition of overweight). Compared to metabolically healthy normal weight individuals, metabolically unhealthy normal weight and overweight individuals had an increased colorectal cancer risk; metabolically healthy overweight individuals had a similar colorectal cancer risk to metabolically healthy normal weight individuals. Among overweight individuals, metabolically healthy individuals had a lower colorectal cancer risk than metabolically unhealthy individuals. Finally, similar associations were seen when the researchers used waist circumference instead of BMI as the measure of adiposity. What Do These Findings Mean? These findings suggest that normal weight individuals with hyperinsulinemia (the metabolically unhealthy normal weight phenotype) have a higher risk of colorectal cancer than normal weight individuals without hyperinsulinemia. They also suggest that metabolically unhealthy overweight individuals have a higher risk of colorectal cancer than metabolically healthy overweight individuals. The accuracy of these findings may be limited by the method the researchers used to classify individuals as hyperinsulinemic—there is no universally accepted clinical definition for using C-peptide level to diagnose hyperinsulinemia. Nevertheless, these findings suggest that the assessment of insulin levels in conjunction with adiposity measures might be a better way to assess an individual’s colorectal cancer risk than simply measuring adiposity, and might help to identify those individuals at high risk of colorectal cancer who are most likely to benefit from targeted interventions designed to prevent the onset of clinical disease. Additional Information This list of resources contains links that can be accessed when viewing the PDF on a device or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001988. The US National Cancer Institute provides information for patients about all aspects of colorectal cancer; it also provides more detailed information colorectal cancer for health professionals and information on cancer risk and obesity The UK National Health Service Choices website has information and personal stories about colorectal cancer and information on obesity The not-for-profit organization Cancer Research UK provides information about colorectal cancer and about the association between cancer and obesity MedlinePlus provides links to further resources about colorectal cancer and about obesity Wikipedia has a page on hyperinsulinemia (note that Wikipedia is a free online encyclopedia that anyone can edit; available in several languages) More information about the EPIC study is available

Published
2016
Full Text
View/download PDF

49. LifeGene—a large prospective population-based study of global relevance

Author

Alexander Ploner, Karl Michaëlsson, Juni Palmgren, Hans-Olov Adami, Markus Maeurer, Göran Pershagen, Lauren Lissner, Leif Groop, Juha Kere, Erik Ingelsson, Patrick F. Sullivan, Catarina Almqvist, Jan-Eric Litton, Nancy L. Pedersen, Paul W. Franks, Gunnel Tybring, Department of Medical Epidemiology and Biostatistics (MEB), Karolinska Institutet [Stockholm], Astrid Lindgren Children's Hospital, Karolinska University Hospital [Stockholm], Department of Epidemiology, Harvard School of Public Health, Department of Public Health & Clinical Medicine, Section for Medicine, Umeå University Hospital Sweden, Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Skåne University Hospital, Lund University [Lund], Department of Clinical Sciences, Diabetes and Endocrinology Unit, Department of Biosciences and Nutrition, Department of Public Health and Community Medicine, University of Gothenburg (GU), Department of Microbiology, Tumor and Cell Biology, Swedish Institute for Infectious Disease Control, Department of Surgical Sciences, Uppsala University, Department of Mathematical Statistics, Stockholm University, Institute of Environmental Medicine, Department of Genetics, University of North Carolina [Chapel Hill] (UNC), and University of North Carolina System (UNC)-University of North Carolina System (UNC)

Subjects
Gerontology, Questionnaires, Adult, medicine.medical_specialty, Pediatrics, Biomedical Research, Adolescent, Epidemiology, Population genetics, media_common.quotation_subject, Population, Communicable Diseases, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Pregnancy, Medicine, Humans, Genetic Predisposition to Disease, 030212 general & internal medicine, Longitudinal Studies, Prospective study, Prospective cohort study, education, Child, 030304 developmental biology, media_common, Biobank, Sweden, 0303 health sciences, education.field_of_study, business.industry, Public health, Infant, Newborn, Infant, Environmental Exposure, Middle Aged, New Study, 3. Good health, Child, Preschool, Cohort, Personal identity, Host-Pathogen Interactions, Female, business, Cohort study
Abstract

International audience; Studying gene-environment interactions requires that the amount and quality of the lifestyle data is comparable to what is available for the corresponding genomic data. Sweden has several crucial prerequisites for comprehensive longitudinal biomedical research, such as the personal identity number, the universally available national health care system, continuously updated population and health registries and a scientifically motivated population. LifeGene builds on these strengths to bridge the gap between basic research and clinical applications with particular attention to populations, through a unique design in a research-friendly setting. LifeGene is designed both as a prospective cohort study and an infrastructure with repeated contacts of study participants approximately every 5 years. Index persons aged 18-45 years old will be recruited and invited to include their household members (partner and any children). A comprehensive questionnaire addressing cutting-edge research questions will be administered through the web with short follow-ups annually. Biosamples and physical measurements will also be collected at baseline, and re-administered every 5 years thereafter. Event-based sampling will be a key feature of LifeGene. The household-based design will give the opportunity to involve young couples prior to and during pregnancy, allowing for the first study of children born into cohort with complete pre-and perinatal data from both the mother and father. Questions and sampling schemes will be tailored to the participants' age and life events. The target of LifeGene is to enrol 500,000 Swedes and follow them longitudinally for at least 20 years.

Published
2010
Full Text
View/download PDF

50. Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort

Author

Amanda J. Cross, Petra H.M. Peeters, Pietro Ferrari, Françoise Clavel-Chapelon, Salvatore Panico, Augustin Scalbert, Anja Olsen, José María Huerta, Paolo Vineis, Gianluca Severi, Eva Ardanaz, H. Bas Bueno-de-Mesquita, Ruth C. Travis, Bénédicte Elena-Herrmann, Nicholas J. Wareham, Pagona Lagiou, Talita Duarte-Salles, Christina Bamia, Anne Tjønneland, Rudolf Kaaks, Bodil Ohlsson, Magdalena Stepien, Antonio Agudo, Krasimira Aleksandrova, Heiner Boeing, Isabelle Romieu, Kay-Tee Khaw, Veronika Fedirko, Domenico Palli, Julie A. Schmidt, Anne Fages, Rosario Tumino, Valeria Pala, Anna Floegel, Dimitrios Trichopoulos, Miren Dorronsoro, Marc J. Gunter, Klas Sjöberg, Clément Pontoizeau, Marie-Christine Boutron-Ruault, Elisabete Weiderpass, Tilman Kühn, Elio Riboli, Mazda Jenab, Antonia Trichopoulou, Esther Molina-Montes, Fages, Anne, Duarte Salles, Talita, Stepien, Magdalena, Ferrari, Pietro, Fedirko, Veronika, Pontoizeau, Clément, Trichopoulou, Antonia, Aleksandrova, Krasimira, Tjønneland, Anne, Olsen, Anja, Clavel Chapelon, Françoise, Boutron Ruault, Marie Christine, Severi, Gianluca, Kaaks, Rudolf, Kuhn, Tilman, Floegel, Anna, Boeing, Heiner, Lagiou, Pagona, Bamia, Christina, Trichopoulos, Dimitrio, Palli, Domenico, Pala, Valeria, Panico, Salvatore, Tumino, Rosario, Vineis, Paolo, Bueno de Mesquita, H. Ba, Peeters, Petra H, Weiderpass, Elisabete, Agudo, Antonio, Molina Montes, Esther, Huerta, José María, Ardanaz, Eva, Dorronsoro, Miren, Sjöberg, Kla, Ohlsson, Bodil, Khaw, Kay Tee, Wareham, Nick, Travis, Ruth C, Schmidt, Julie A, Cross, Amanda, Gunter, Marc, Riboli, Elio, Scalbert, Augustin, Romieu, Isabelle, Elena Herrmann, Benedicte, Jenab, Mazda, ISA NMR Methods for Metabolism - Methodes RMN en métabolomique (2014-2018), Institut des Sciences Analytiques (ISA), Institut de Chimie du CNRS (INC)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), ISA - Centre de RMN à très hauts champs, Centre International de Recherche contre le Cancer - International Agency for Research on Cancer (CIRC - IARC), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), parent, International Agency for Cancer Research (IACR), Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School [Athens], Department of Epidemiology, Deutsches Institut für Ernahrungsforschung Potsdam-Rehbrücke (DIFE), Institute of Cancer Epidemiology, Danish Cancer Society, Department of Food Science [Copenhagen] (UCPH FOOD), Faculty of Science [Copenhagen], University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut Gustave Roussy (IGR), Human Genetics Foundation (HuGeF), Università degli studi di Torino (UNITO), Division of Cancer Epidemiology, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Thermo Fisher Scientific, Thermo Fisher Scientific Inc., German Institute of Human Nutrition Potsdam-Rehbruecke, German Institute of Human Nutrition, Harvard School of Public Health, WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute – ISPO, Nutritional Epidemiology Unit, National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH)-National Institutes of Health [Bethesda] (NIH)-IRCCS Foundation, Department of Clinical and Experimental Medicine, Università degli studi di Napoli Federico II, Cancer Registry and Histopathology Unit, Civile - M.P.Arezzo Hospital, Department of Epidemiology and Biostatistics, MRC-HPA Centre for Environment and Health, School of Public Health, Imperial College London, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Julius Center for Health Sciences and Primary Care, VU University Medical Center [Amsterdam], Imperial College London-School of public health, The University of Hong Kong (HKU)-The University of Hong Kong (HKU), Department of Community Medicine, University of Tromsø (UiT), Department of Research, Cancer Registry of Norway-Samfundet Folkhälsan, Helsinki, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet [Stockholm], Institut Català d'Oncologia, Spain Institute of Oncology, Andalusian School of Public Health [Granada], Consortium for Biomedical Research in Epidemiology and Public Health, CIBER de Epidemiología y Salud Pública (CIBERESP), Danish Cancer Society Research Center, Murcia Regional Health Council, Sección de Epidemiología de Enfermedades No Transmisibles, Navarre Public Health Institute, Epidemiology and Health Information, Public Health Department of Gipuzkoa, Volvo, VOLVO-VOLVO, Skane University Hospital [Lund], University of Cambridge School of Clinical Medicine, MRC epidemiology Unit, Addenbrooke's Hospital, Cancer Epidemiology Unit, University of Oxford [Oxford], Laboratoire d'informatique Fondamentale de Marseille (LIF), Centre National de la Recherche Scientifique (CNRS)-École Centrale de Marseille (ECM)-Aix Marseille Université (AMU), School of Public Health [London, UK] (Faculty of Medicine), Imperial College London, Department of Chemistry, University of Cambridge [UK] (CAM), Nutrition and Metabolism Section, Biomarkers Group, Nutrition and Metabolism Section, This work was supported by the French National Cancer Institute (L'Institut National du Cancer, INCA, grant number 2009-139, PI: M. Jenab). AF received financial support (BDI fellowship) from the Centre National de la Recherche Scientifique (CNRS) and Bruker Biospin. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, and Institut National de la Sante et de la Recherche Medicale (INSERM) (France), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum (DKFZ), and Federal Ministry of Education and Research (Germany), Hellenic Health Foundation (Greece), Italian Association for Research on Cancer (AIRC), National Research Council, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, and AIRE-ONLUS Ragusa, AVIS Ragusa, Sicilian Government (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (the Netherlands), European Research Council (ERC, grant number ERC-2009-AdG 232997) and Nordforsk, and Nordic Center of Excellence Programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS), Regional Governments of Andalucia, Asturias, Basque Country, Murcia (No. 6236) and Navarra, and ISCIII RETIC (RD06/0020) (Spain), Swedish Cancer Society, Swedish Scientific Council, and Regional Government of Skane and Vasterbotten (Sweden), Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and Wellcome Trust (UK). The funders had no role in the study design, data collection, analysis, and interpretation presented in this article. They were neither involved in the writing of the manuscript, nor in the decision to submit it for publication., Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Centre Européen de Résonance Magnétique Nucléaire à Très Hauts Champs (CERMNTHC), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Hôpital Paul Brousse-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), 'Civile M. P. Arezzo' Hospital, Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), [Fages,A, Pontoizeau,C, Elena-Herrmann,B] Institut des Sciences Analytiques, Centre de RMN à très hauts champs, CNRS/ENS Lyon/UCB Lyon-1, Université de Lyon, Villeurbanne, France. [Duarte-Salles,T, Stepien,M, Ferrari,P, Scalbert,A, Romieu,I, Jenab,M] International Agency for Research on Cancer (IARC-WHO), Lyon, France. [Fedirko,V] Department of Epidemiology, Rollins School of Public Health, Winship Cancer Institute, Emory University, Atlanta, USA. [Trichopoulou,A] Hellenic Health Foundation, Athens, Greece. Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece. [Aleksandrova,K, Floegel,A, Boeing,H] Department of Epidemiology, German Institute of Human Nutrition (DIfE), Potsdam-Rehbrücke, Germany. [Tjønneland,A, Olsen,A] Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark. [Clavel-Chapelon,F, Boutron-Ruault,M] INSERM, Centre for Research in Epidemiology and Population Health (CESP), nutrition, Hormones and Women’s Health Team, Villejuif, France. Université Paris Sud, Villejuif, France. Institut Gustave Roussy, Villejuif, France. [Severi,G, Vineis,P] Human Genetics Foundation (HuGeF), Torino, Italy. [Kaaks,R, Kuhn,T] Department of Cancer Epidemiology, German Cancer Research Centre, Heidelberg, Germany. [Lagiou,P, Bamia,C] Department of Hygiene, Epidemiology, and Medical Statistics, University of Athens Medical School, Goudi, Athens, Greece. [Lagiou,P, Trichopoulos,D] Department of Epidemiology, Harvard School of Public Health, Boston, USA. [Palli,D] Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute – ISPO, Florence, Italy. [Pala,V] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. [Panico,S] Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy. [Tumino,R] Cancer Registry and Histopathology Unit, 'Civic - M.P. Arezzo' Hospital, Ragusa, Italy. [Vineis,P, Peeters,PH] MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK. [Bueno-de-Mesquita,HB] Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands. Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. [Bueno-de-Mesquita,HB, Cross,A, Gunter,M, RibolI,E] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [Peeters,PH] Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. [Weiderpass,E] Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. Department of Research, Cancer Registry of Norway, Oslo, Norway. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Samfundet Folkhälsan, Helsinki, Finland. [Agudo,A] Unit of Nutrition and Cancer, IDIBELL, Catalan Institute of Oncology-ICO, L’Hospitalet de Llobregat, Barcelona, Spain. [Molina-Montes,E] Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. [Molina-Montes,E, Huerta,JM, Ardanaz, E] CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Huerta,JM] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Ardanaz,E] Navarre Public Health Institute, Pamplona, Spain. [Dorronsoro,M] Public Health Direction and Biodonostia CIBERESP, Basque Regional Health Department, San Sebastian, Spain. [Sjöberg,K] Department of Clinical Sciences, Lund University, Malmö, Sweden. Department of Gastroenterology and Nutrition, Skåne University Hospital, Malmö, Sweden. [Ohlsson,B] Department of Clinical Sciences, Division of Internal Medicine, Skåne University Hospital, Lund University, Malmö, Sweden. [Khaw,K] University of Cambridge School of Clinical Medicine, Clinical Gerontology Unit, Addenbrooke’s Hospital, Cambridge, UK. [Wareham,N] MRC Epidemiology Unit, University of Cambridge, Cambridge, UK. [Travis,RC, Schmidt,JA] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., This work was supported by the French National Cancer Institute (L’Institut National du Cancer, Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France), Health Research Fund (FIS), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (No. 6236) and Navarra, and ISCIII RETIC (RD06/0020) (Spain), Swedish Cancer Society, Swedish Scientific Council, and Regional Government of Skåne and Västerbotten (Sweden), Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and Wellcome Trust (UK). The funders had no role in the study design, data collection, analysis, and interpretation presented in this article. They were neither involved in the writing of the manuscript, nor in the decision to submit it for publication, Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Università degli studi di Torino = University of Turin (UNITO), University of Naples Federico II = Università degli studi di Napoli Federico II, and University of Oxford

Subjects
Oncology, Male, Neoplasias Hepáticas, Cirrhosis, Magnetic Resonance Spectroscopy, Epidemiology, Hepatocellular carcinoma, Nuclear magnetic resonance, Cohort Studies, Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma::Carcinoma, Hepatocellular [Medical Subject Headings], 0302 clinical medicine, Risk Factors, Prospective Studies, Prospective cohort study, CIRRHOSIS, Early Detection of Cancer, Medicine(all), 0303 health sciences, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [Medical Subject Headings], Liver Neoplasms, Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biochemistry::Metabolomics [Medical Subject Headings], Metabolómica, Estudios Prospectivos, General Medicine, Middle Aged, CANCER, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Europe, Liver Neoplasm, 030220 oncology & carcinogenesis, Female, Liver cancer, Case-Control Studie, Life Sciences & Biomedicine, Metabolomics, Carcinoma Hepatocelular, Research Article, Human, Adult, medicine.medical_specialty, Carcinoma, Hepatocellular, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], TISSUE METABOLOMICS, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Smoking [Medical Subject Headings], Metabolomic, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus [Medical Subject Headings], Càncer de fetge, 03 medical and health sciences, Medicine, General & Internal, [CHIM.ANAL]Chemical Sciences/Analytical chemistry, IDENTIFY SERUM BIOMARKERS, Internal medicine, General & Internal Medicine, medicine, Humans, Obesity, Epidemiologia, 030304 developmental biology, FATTY LIVER-DISEASE, Aged, Hepatitis, Science & Technology, business.industry, Case-control study, METABONOMICS, Cancer, MASS-SPECTROMETRY, medicine.disease, NMR, Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings], Prospective Studie, Case-Control Studies, DISCOVERY, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Drinking Behavior::Alcohol Drinking [Medical Subject Headings], Immunology, RISK-FACTORS, Cohort Studie, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Background: Hepatocellular carcinoma (HCC), the most prevalent form of liver cancer, is difficult to diagnose and has limited treatment options with a low survival rate. Aside from a few key risk factors, such as hepatitis, high alcohol consumption, smoking, obesity, and diabetes, there is incomplete etiologic understanding of the disease and little progress in identification of early risk biomarkers. Methods: To address these aspects, an untargeted nuclear magnetic resonance metabolomic approach was applied to pre-diagnostic serum samples obtained from first incident, primary HCC cases (n = 114) and matched controls (n = 222) identified from amongst the participants of a large European prospective cohort. Results: A metabolic pattern associated with HCC risk comprised of perturbations in fatty acid oxidation and amino acid, lipid, and carbohydrate metabolism was observed. Sixteen metabolites of either endogenous or exogenous origin were found to be significantly associated with HCC risk. The influence of hepatitis infection and potential liver damage was assessed, and further analyses were made to distinguish patterns of early or later diagnosis. Conclusion: Our results show clear metabolic alterations from early stages of HCC development with application for better etiologic understanding, prevention, and early detection of this increasingly common cancer., This work was supported by the French National Cancer Institute (L’Institut National du Cancer; INCA; grant number 2009-139; PI: M. Jenab). AF received financial support (BDI fellowship) from the Centre National de la Recherche Scientifique (CNRS) and Bruker Biospin. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum (DKFZ), and Federal Ministry of Education and Research (Germany); Hellenic Health Foundation (Greece); Italian Association for Research on Cancer (AIRC), National Research Council, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, and AIRE-ONLUS Ragusa, AVIS Ragusa, Sicilian Government (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (the Netherlands); European Research Council (ERC; grant number ERC-2009-AdG 232997) and Nordforsk, and Nordic Center of Excellence Programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (No. 6236) and Navarra, and ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Scientific Council, and Regional Government of Skåne and Västerbotten (Sweden); Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and Wellcome Trust (UK).

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results